1	Plasma Microbial Cell-free DNA Sequencing from Over 15,000 Patients Identified a Broad Spectrum of
2	Pathogens
3	Sarah Y. Park ^a , Eliza J Chang ^a , Nathan Ledeboer ^b , Kevin Messacar ^c , Martin S. Lindner ^a , Shivkumar
4	Venkatasubrahmanyam ^a , Sivan Bercovici ^a , Judith C. Wilber ^a , Marla Lay Vaughn ^a , Bradley A. Perkins ^a , and
5	Frederick S. Nolte ^a *
6	^a Karius, Redwood City, CA
7	^b Medical College of Wisconsin, Milwaukee, WI
8	^c University of Colorado, Children's Hospital Colorado, Aurora, CO.
9	*Corresponding author contact information:
10	Karius, Inc.
11	975 Island Drive, Suite 101
12	Redwood City, CA 94065
13	rick.nolte@kariusdx.com
14	
15	Abstract word count: 276
16	Text word count: 3,702
17	
18 19	Keywords: microbial cell-free DNA, high-throughput nucleic acid sequencing, liquid biopsy for infectious diseases, metagenomics

ABSTRACT

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Microbial cell-free DNA (mcfDNA) sequencing is an emerging infectious disease diagnostic tool which enables unbiased pathogen detection from plasma. The Karius Test®, a commercial mcfDNA sequencing assay developed by and available since 2017 from Karius, Inc. (Redwood City, CA), detects and quantifies mcfDNA as molecules/µl in plasma. The commercial sample data and results for all tests conducted from April 2018 through mid-September 2021 were evaluated for laboratory performance metrics. reported pathogens, and data from test requisition forms. A total of 18,690 reports were generated from 15,165 patients in a hospital setting among 39 states and the District of Columbia. The median time from sample receipt to reported result was 26 hours (IQR 25-28), and 96% of samples had valid test results. Almost two-thirds (65%) of patients were adults, and 29% at the time of diagnostic testing had ICD10 codes representing a diverse array of clinical scenarios. There were 10,752 (58%) reports that yielded at least one taxon for a total of 22,792 detections spanning 701 unique microbial taxa. The 50 most common taxa detected included 36 bacteria, 9 viruses, and 5 fungi. Opportunistic fungi (374 Aspergillus spp., 258 Pneumocystis jirovecii, 196 Mucorales, and 33 dematiaceous fungi) comprised 861 (4%) of all detections. Additional diagnostically challenging pathogens (247 zoonotic and vector borne pathogens, 144 Mycobacteria, 80 Legionella spp., 78 systemic dimorphic fungi, 69 Nocardia spp., and 57 protozoan parasites) comprised 675 (3%) of all detections. We report the largest cohort of patients tested using plasma mcfDNA sequencing. The wide variety of pathogens detected by plasma mcfDNA sequencing reaffirm our understanding of the ubiquity of some infections while also identifying taxa less commonly detected by conventional methods.

INTRODUCTION

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

Sequencing microbial cell-free DNA (mcfDNA) in plasma represents integration of progress in genomic sequencing, computation analyses, and recognition of cell-free DNA as a clinically useful blood analyte (1-3). Over the last four decades, PCR-based tests, specifically multiplexed broad syndromic panels, have made welcomed contributions to infectious disease diagnostics but fall short of desired performance including breadth of pathogen detection and require samples of infected tissue or body fluid (4). Broad range PCR testing arguably facilitates considering a wider range of potential pathogens but is still only limited to bacteria and fungi (5). A recent meta-analysis, which included 20 studies that satisfied the Quality Assessment of Diagnostic Accuracy Studies (6) to assess the diagnostic accuracy of next generation sequencing in distinguishing infectious diseases, concluded that this group of technologies demonstrated satisfactory diagnostic performance for infections and yielded an overall detection rate superior to conventional methods (7). Four of the studies included in this review employed plasma mcfDNA sequencing. Moreover, early experience with plasma mcfDNA sequencing suggests this new approach, especially when applied early in a patient's clinical course and for specific use cases, has potential to improve upon the above-noted shortcomings (8, 9). Plasma mcfDNA sequencing enables unbiased pathogen detection through noninvasive sampling with rapid turnaround, creating opportunities to enhance diagnosis of bloodstream and deep-seated infections (10-12). This is urgently needed particularly among immunocompromised patients who are often the most vulnerable to serious and frequently life-threatening infections.

The Karius Test® is an analytically and clinically validated mcfDNA sequencing test, commercially available for US inpatients since 2017 as a laboratory developed test from Karius, Inc. The test can identify and quantitate molecules/µl (MPM) mcfDNA in plasma from >1,500 bacteria, DNA viruses, fungi, and parasites. The analytical and clinical validation of the test was previously reported (12). Since the time of this study, others have reported how this unbiased test may contribute to the diagnosis and

management of life-threatening infections in defined patient populations, specifically immunocompromised patients early in their clinical course, by creating the potential to minimize invasive procedures (13), reducing time to specific etiologic diagnosis of infections compared with standard of care (SOC) microbiological testing (14), and, in some cases, optimizing antimicrobial therapy (15, 16). In contrast, several retrospective, observational reviews of Karius Test utilization concluded that in routine clinical practice the diagnostic and clinical impact of the test was limited, which highlights the need for diagnostic stewardship to optimize implementation and maximize clinical utility in specific patient populations (17-19).

Plasma mcfDNA sequencing for infectious disease diagnosis performance at scale with respect to time to results, quality metrics, positivity rates, and diversity of taxa detected has not been previously reported. Here we review the results for a large commercial laboratory testing cohort of over 18,000 plasma samples from over 15,000 patients in a hospital setting with the primary objective to provide additional insights about the breadth and depth of microbial identifications. In the course of doing so, we also describe the current test performance metrics and characterize clinical use based on the limited available data.

MATERIAL AND METHODS

Commercial laboratory test cohort. The Karius Test results for patients from across the United States were evaluated for reported pathogens and patient data (including basic demographics, ordering clinician, and ICD-10 codes if provided) obtained from the test request forms (TRF) for all samples tested from April 1, 2018 through mid-September, 2021. Laboratory performance metrics were gathered for all samples collected from April 1, 2018 through the end of September, 2021. Diagnosis codes submitted via TRFs were summarized at both the chapter level and Clinical Classifications Software

Refined Categories (20, 21). Immunocompromising conditions were then flagged using definitions published by the Agency for Healthcare Research and Quality (22-24).

The Karius Test. Plasma mcfDNA sequencing was performed as previously described (12) in the Karius clinical laboratory, certified under the Clinical Laboratory Improvement Amendments of 1988 and accredited by the College of American Pathologists. Briefly, whole-blood samples were collected in either BD Vacutainer plasma preparation tubes (PPTs) or K2-EDTA tubes. After plasma has been separated from cells, the sample is stable at ambient temperature for 96 hours and at -20°C for 6 months. Upon receipt at Karius, controls for carry-over, sequencing bias, metagenomic sequencing quality, and sample mix-ups were added to the sample. Proprietary chemistries were used to enrich samples for mcfDNA without preselecting pathogens to test. Automated DNA extraction and sequencing library preparation protocols were optimized for high speed and low pathogen bias. Single-end, 76-cycle sequencing was performed on NextSeq 500 instruments (Illumina, San Diego, CA) with an average of >20 million reads/sample. Double-unique dual indexes were used to ensure robust sample demultiplexing. Sequencing data were processed using a proprietary analytical pipeline, and microbial reads were aligned to a database comprising >20,000 curated assemblies from >16,000 species of which >1,500 taxa are reported, including bacteria, DNA viruses, fungi, and parasites (https://kariusdx.com/the-karius-test/pathogen-list/).

Microorganisms present in statistically significant amounts were reported as a concentration of their mcfDNA expressed as MPM, a unique, absolute quantification capability of the Karius Test shown in preliminary work to correlate well with single-analyte quantitative PCR measurements (25, 26). The reports also contained median and range of MPM values observed for each microorganism reported in the last 1,000 specimens, as MPM values from different microbes are not comparable, and a reference interval determined from 675 asymptomatic donors for comparison. We routinely analyzed the raw data for mcfDNA from potential pathogens, including those present at levels below our standard

laboratory report thresholds. For this study, we focused on microorganisms identified in statistically significant amounts.

Notable improvements in the test wet bench procedures and analytical pipeline, as may be anticipated, occurred during the study period. We used the operational classes of pathogens described by Relman, Falkow, and Ramakrishnan (27). The operational classes include obligate, commensal, zoonotic, and environmental pathogens.

Data analytics. Data analysis and visualization were conducted using Python v. 3.9.7, pandas v. 1.3.4, matplotlib v. 3.4.3, and seaborn v. 0.11.2 (28-30). Given the taxonomy and nomenclature for some genera continue to evolve, we selected three (*Legionella*, *Nocardia*, and *Mycobacterium*) to examine species detections, especially multiple species co-detections, more closely.

RESULTS

Test cohort. A total of 19,739 samples meeting collection and transport requirements were tested from 16,172 patients in a hospital setting in 39 states and the District of Columbia during the study period. The median time from sample receipt at the Karius laboratory to reported result was 26 hours (IQR 25–28), and 96% of samples had valid test results. A summary of key performance metrics for the test in this production data set are shown in Table 1. These metrics were not significantly different (two-sided t-test p-value >0.01) from those reported for the first 2,000 clinical samples run by the Karius clinical laboratory and reported in the initial validation study (12). Infectious disease and hematology/oncology providers represented most ordering clinicians, 64% (n=9,804) and 14% (n=2,132), respectively, for the 15,424 specimens with a National Provider Identifier indicated. We were able to capture and analyze 18,690 reports from 15,165 patients. Twelve percent (n=1,839) of patients had at least one repeat test during the study interval. Almost two thirds (65%, n=9,798) of patients were adults (i.e., age >18 years). More than a quarter (29%, n=4,423) of patients at the time of diagnostic testing

had ICD10 codes representing a diverse array of clinical scenarios indicated in their TRFs (**Table 2**). Eighteen percent (n=797) of these patients were indicated as immunocompromised (IC); 717 (16%) had fever; and 230 (5%) had sepsis.

Taxa detection and quantification. Of samples yielding a valid result, 7,938 (42%) reported a negative test with no pathogens identified. The remaining 10,752 (58%) Karius Test reports from 8,849 patients had at least one microbe identified (5,531 [30%] only one) representing 701 unique microbial taxa (526 [75%] bacteria, 103 [15%] fungi, 47 [7%] viruses, and 24 [3%] parasites) and a total of 22,792 detections. The overall frequency of detection for each of these groups is shown in Fig. 1, and the number of detected taxa counts per report for all positive reports is shown in Fig. 2. All the quality control metrics were met for taxa quantification in MPM for 9,690 (90%) samples with positive results. A complete list of all taxa reported along with their frequency of detection and median and IQR for the MPM values are given in Supplemental Table 1.

Top 50 reported taxa. The top 50 reported taxa and the median, range, and IQR of MPM for each taxon are shown in **Table 3**. They included 36 bacteria, 9 viruses, and 5 fungi. Together the top 50 taxa included a broad range of commensal and environmental pathogens and represented 15,692 detections (69% of all detections).

The distribution of these taxa are as follows. There were 11,023 detections of bacteria including 11 anaerobes (2,730, 25%), 8 *Streptococcus* spp. (1,379, 12%), 4 *Enterobacterales* (2,031, 18%), 3 *Staphylococcus* spp. (1,369, 12%)., 2 *Rothia* spp. (564, 5%), 2 *Haemophilus* spp. (466, 4%), 2 *Enterococcus* spp. (1,092, 10%), and 1 each of *Acinetobacter haemolyticus* (199, 2%), *Pseudomonas aeruginosa* (817, 7%), *Stenotrophomonas maltophilia* (169, 1%), and *Helicobacter pylori* (207, 2%). There were 3,982 viral detections of 9 different viruses that included 1,275 (32%) cytomegalovirus, 902 (23%) Epstein-Barr virus, 479 (12%) herpes simplex virus 1, 468 (12%) human herpes virus 6B, 354 (9%) BK polyoma virus, 171 (4%) human adenovirus C, 135 (3%) torque teno virus (TTV), 100 (3%) human adenovirus B, and 98

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

(3%) human herpes virus 7. Finally, there were 920 detections of fungi comprising 260 (28%) Candida albicans, 258 (28%) Pneumocystis jirovecii, 186 (20%) Asperaillus fumigatus, 113 (12%) Candida glabrata, and 103 (11%) Candida tropicalis. Difficult to diagnose uncommon pathogens. The SOC methods for the organisms listed below have considerable shortcomings including, but not limited to, sensitivity and specificity, comprehensiveness, accuracy, time to result, and/or local availability. Bacteria. The frequency distribution of the number of detections of Legionella-like organisms (n=80) is shown in Fig. 3. Forty-one percent of these detections were the most recognized pathogen, L. pneumophila. Two reports contained co-detections of two different species (L. brunensis, 400 MPM and L. hackeliae, 270 MPM; and L. feeleii, 78,508 MPM and L. tunisiensis, 76,445 MPM, respectively). Neither L. brunensis nor L. tunisiensis has been associated with human disease (https://specialpathogenslab.com/legionella-species/), and the MPM values for the co-detections in each report were similar. The frequency distribution of *Nocardia* spp. detections, n=76, is shown in **Fig. 4**. Plasma mcfDNA sequencing detected 25 of the approximately 100 validly named species. Of the 8 species reported to be isolated more frequently from patients, 7 were detected (Fig. 4). One species, N. cyriacigeorgica, dominated with 19 (25%) detections. Of the 69 patient reports represented by the Nocardia spp. detections, 12 (17%) reported ≥2 concurrent species (range 2–5). All the co-detections were reported with similar MPM values, and 8 (67%) were co-detections of closely related species (4 N. exalbida/gamkensis, 3 N. elegans/nova/africana, 1 N. kruczakiae/violaceofusca/aobensis) previously reported to be indistinguishable by mcfDNA sequencing (31, 32). The frequency distribution of the 156 Mycobacterium spp. detections is shown in Fig 5. Plasma

mcfDNA sequencing detected 107 (69%) slowly growing mycobacteria (SGM) and 49 (31%) rapidly

growing mycobacteria (RGM). The frequency of species distributions of these three genera showed similarities in that several species were predominant, followed by long tails of uncommon to single species detections. We reported ≥2 concurrent species (range 2–6) in 6 (4%) of the 144 reports including *Mycobacterium* spp. All the co-detections were reported with similar MPM values. Three of the reports contained *M. avium complex/chimera* and one each *M. avium* complex/celatum/kyorinense, *M. brisbanense/mucogenicum/obuense*, and *M. chubuense/elephantis/flavescens/goodii/holsaticum* /phlei. The co-detections of multiple *Legionella*, *Nocardia*, and *Mycobacterium* spp., respectively, within the same patient are shown in **Supplemental Table 2**.

The frequency distribution of the 247 (3% of all bacterial detections) zoonotic and vector borne bacterial detections are shown in **Fig. 6**. *Bartonella henselae* predominated with 90 (36%) detections.

Fungi. The frequency distribution of the 632 *Candida* spp. detections is shown in **Fig 7**; 374

Aspergillus spp. detections in **Fig 8**; 196 detections in the order *Mucorales* in **Fig. 9**; 78 detections of the systemic dimorphic fungi in **Fig. 10**; and 33 detections of dematiaceous fungi in **Fig. 11**. We detected 9 microsporidia, including 5 *Enterocytozoon bieneusi* and one each of *E. cuniculi, E. hellem, Anncaliia algerae*, and *Vittaforma corneae*. In addition, *Pneumocystis jirovecii* (258 detections) was among the top 50 taxa detected.

<u>Eukaryotic parasites</u>. The frequency distribution of the 57 (89% of 64 parasite detections) protozoa is shown in **Fig. 12**. Among the protozoan parasite detections, 68% were *Toxoplasma gondii*, and 14% were pathogenic amoebae. Among the 7 (11%) helminthic parasites, we detected 4 nematodes (all *Strongyloides stercoralis*), 2 cestodes (both *Echinococcus multilocularis*), and 1 trematode (*Schistosoma mansoni*).

DISCUSSION

We report the largest testing cohort of patients in which mcfDNA was identified and quantified. The key test performance metrics in this large cohort mirror what was reported with a much smaller cohort in the initial validation study (10), demonstrating that the Karius Test is robust and can be performed at scale in a clinically relevant time frame. These mcfDNA sequencing data reaffirm the ubiquity of some infections, as commonly expected microbes were detected in most patients while less common microbes were rarely detected. However, notably, the unbiased approach of the plasma mcfDNA sequencing made those "rare" detections possible, whereas conventional diagnostics require targeting specific organisms. Identifying optimal utilization, both clinical indications and timing, of the plasma mcfDNA sequencing in future studies to augment clinical decision-making and integration into current testing algorithms (17, 18, 33-35) will serve to improve the utility of the test. Examples of such studies include two recently completed prospective, observational clinical trials of the use of the Karius Test to diagnose pneumonia in immunocompromised patients (NCT04047719) (36) and infections in stem cell transplant inpatients and outpatients over time (NCT02804464) (26), respectively.

Our finding that 58% of the Karius Test reports identified ≥1 pathogen is substantially lower than the 70–85% reported for the test when applied to well-defined clinical uses (13, 14, 37). These findings support the need for diagnostic stewardship and additional clinical studies demonstrating how yield differs and should be carefully interpreted according to the specific patient population and disease prevalence considered.

The Karius Test quantitates detections in MPM, which can be influenced by several factors specific to the microbial genome—e.g., turnover rate and genome size (12). Confounding patient variables (e.g., infection site, therapeutic interventions, and immune status) may also influence this measure. Generally higher concentrations have been found in definite infections, but since considerable overlap of MPM values exists in unlikely infections and in the asymptomatic cohort, threshold values for definite infections have not been established (12). However, following the decay of mcfDNA

quantitatively by serial testing may have important implications for individual patient management in assessing the effectiveness of antimicrobial therapy and other medical or surgical interventions (8, 38, 39), but needs further study.

Notable among the most common detections were the many commensal bacterial and fungal pathogens that cause serious and often invasive infections in patients with relevant risk factors (e.g., immunocompromised). Among the viruses most detected by the Karius Test (e.g., *Herpesviridae*), all could represent latent infection, reactivation, or active infections depending on the respective clinical conditions; regardless, the detection of these viruses may be of particular concern for immunocompromised patients for whom they may cause considerable morbidity (40).

A key benefit of unbiased mcfDNA sequencing identified in this study is the ability to detect diagnostically challenging microbes such as opportunistic and systemic dimorphic fungi and zoonotic and vector borne pathogens (41). These pathogens often carry a sense of urgency for the management of the individual patient and even for the public's health, as they may be associated with considerable morbidity and potential mortality. As some are uncommonly expected pathogens, they present a major challenge for clinicians in considering and ordering appropriate SOC testing to capture all possible pathogens. For the laboratories, the microbiologic diagnosis of these infections often represents a major challenge for SOC methods as has been described by others (42, 43).

The absence of certain pathogens such as the emerging, multidrug resistant *C. auris* among the detections may arguably reflect the relatively few cases occurring during the study period in the geographic locations or patient populations of the test cohort and reflects the rarity of clinical cases in the United States (44). Plasma mcfDNA sequencing has the potential to contribute to the greater understanding of the geographic distribution of microbes and even overall disease surveillance, as demonstrated by the systemic dimorphic fungi detections. At 43 detections (55% of dimorphic fungal

identifications), *Histoplasma capsulatum* predominated, very likely related to its wide geographic range and opportunities for environmental exposure and mirrors what is known about the epidemiology and incidence of systemic dimorphic fungal infections (45). The relative frequency of detections of *Coccidioides immitis* and *posadasii* and *Blastomyces dermatidis* may have been influenced by the geographic bias in this study sample cohort. Of the nine *Cryptococcus* spp. detected, *gattii* was detected only once compared with *neoformans*, reflecting its restricted geographic distribution and the overall rarity of infections in the United States (46).

Among the rarely detected microbes during the study period are some deserving further mention. The detection of *Legionella*, an obligate pathogen, signals public health concern, whether community or hospital acquired. *L. pneumophila* serogroup 1 (LP1) is estimated to cause 84% of community acquired Legionnaire's disease (LD) (47); however, other serogroups of *L. pneumophila* and other *Legionella* spp. may cause 60% of hospital acquired LD (48). Urinary antigen detection is the most common diagnostic in the United States and Europe; yet, given its specificity for LP1, as many as 40–50% of patients with non-LP1 legionellosis could be missed (49, 50). Plasma mcfDNA sequencing provides comprehensive testing for *Legionella* and *Legionella*-like organisms in one diagnostic test and could thereby expand the known LD epidemiology, particularly in nosocomial cases.

Nocardia have 8 species-specific drug susceptibility patterns (51). While accurate species identification can predict antimicrobial susceptibility patterns, molecular methods are required for accurate identifications but are not widely available. The Karius Test detected in our cohort 7 of the 8 species with recognized susceptibility patterns and can provide results more rapidly than existing approaches to species identification.

Finally, culture for mycobacteria, while a complicated and lengthy process, is considered the gold standard, supplemented by direct detection of *M. tuberculosis* complex by nucleic acid

amplification tests (NAATs) in many laboratories. However, NAATs for the direct detection of nontuberculous mycobacteria are not widely available, and accurate identification to species level from cultured isolates remains challenging for most laboratories. The *M. chimaera* may be overrepresented in our cohort since the Karius Test was optimized for its detection following reports of infections occurring post-surgeries employing contaminated cardiopulmonary bypass devices (52). However, these detections demonstrate the capability of mcfDNA sequencing to provide comprehensive identification of these important obligate and commensal pathogens directly from plasma and provides increased diagnostic value to the above-mentioned SOC methods (53).

Plasma mcfDNA sequencing offers a non-invasive means of detecting microbial infection and capturing species diversity, potentially revealing new insights on genetic complexity not resolved by current taxonomic classification. Still, our findings highlight the need to expand currently available genomic sequencing libraries as many species across various genera remain undiscovered or undescribed (54, 55). The species co-detections demonstrated among the genera we highlighted, *Legionella, Nocardia,* and *Mycobacteria,* specifically those occurring at similar MPM values, suggest detection of a single divergent strain, a species not in the Karius Test database, or, alternatively, true polymicrobial detections. Similar challenges exist for broad range PCR testing (5, 56) and occurred with adoption of proteomic identification by MALDI-TOF mass spectrometry (57).

This study has several limitations preventing us from directly comparing and fully elucidating plasma mcfDNA sequencing impact on patient care. Orthogonal testing data (including type, timing, and results) were not available for comparison with the Karius Test results; nor was information regarding antimicrobial or other therapies or procedures. Also, the clinical context for using the Karius Test was provided in only 29% of patients; that information was voluntarily provided, may have been incomplete, and would reflect the clinician's perspective at the time they ordered the test vs. the final diagnosis. However, others have reported potential increased diagnostic yield of plasma mcfDNA sequencing

compared with SOC tests in certain clinical scenarios (14-16, 58). Some have noted the test to be commonly applied in managing severely ill, especially IC, patients (59), who are more likely to be infected with unusual, and difficult to diagnose pathogens (60, 61).

Constraints of the underlying data structure prevented analyzing the data from those patients who had repeated testing to determine whether these tests were performed serially to diagnose new suspected infections or to monitor therapy response or conduct pathogen surveillance among immunocompromised patients as suggested by others (8, 26, 62-64). Further, the underlying data structure limited our ability to stratify the results by notable improvements to the bioinformatics pipeline over the course of the study period. Nevertheless, the unique data from this large testing cohort provides a wealth of information to help improve our understanding of infecting pathogens.

Unbiased plasma mcfDNA sequencing can potentially enhance patient outcomes by direct and timely recognition of pathogens in specific clinical scenarios as well as benefit the overall public health by increasing our understanding of the epidemiology of emerging infectious diseases such as monkeypox virus or *Borrelia miyamotoi* (M.S. Lindner, K. Brick, N. Noll, S.Y. Park, *et. al.*, submitted for publication; L.A. Rubio, A.M. Kjemtrup, G.E. Marx, S. Cronan, *et. al.*, submitted for publication, respectively). Further, this powerful, novel diagnostic tool may facilitate medical advances through recognizing previously unanticipated pathogens, as noted when mcfDNA sequencing was leveraged in a research use only modality to identify porcine cytomegalovirus infection in a patient who had received a genetically modified porcine-to-human cardiac transplant (65). As with any advanced diagnostic tool, careful, timely clinical application with expert guidance and interpretation of its results as well as appropriate diagnostic stewardship will optimize its application to offer even greater clinical impact. In addition, the development of robust clinical outcomes studies to evaluate the clinical impact and cost effectiveness of plasma mcfDNA sequencing for specific clinical indications to guide use remains a top diagnostic stewardship priority.

ACKNOWLEDGEMENTS

We thank the talented, experienced, and dedicated clinical laboratory operations and analytics teams at Karius for generating the test results and sequencing analyses, respectively, that were foundational to this study. We also thank T. Matthew Hill, PharmD, PhD, formerly with Karius, Inc., and Asim A. Ahmed, MD for their early contributions to the paper. This study was supported by Karius. Nathan Ledeboer, PhD and Kevin Messacar, MD, PhD both serve as uncompensated consultants for Karius on this manuscript. Their relationship with Karius has been reviewed and approved by the Medical College of Wisconsin and the University of Colorado, Children's Hospital of Colorado, respectively, in accordance with their conflict of interest policies.

REFERENCES

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

1. Levy SE, Myers RM. 2016. Advancements in Next-Generation Sequencing. Annu Rev Genomics Hum Genet 17:95-115. 2. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment search tool. J Mol Biol 215:403-10. 3. Kowarsky M, Camunas-Soler J, Kertesz M, De Vlaminck I, Koh W, Pan W, Martin L, Neff NF, Okamoto J, Wong RJ, Kharbanda S, El-Sayed Y, Blumenfeld Y, Stevenson DK, Shaw GM, Wolfe ND, Quake SR. 2017. Numerous uncharacterized and highly divergent microbes which colonize humans are revealed by circulating cell-free DNA. Proc Natl Acad Sci U S A 114:9623-9628. 4. Lewinski M, Alby K, Babady E, Butler-Wu S, Dien Bard J, Greninger A, Hanson K, Naccache S, Newton D, Temple-Smolkin RL, Nolte F. in press. Exploring the Utility of Multiplex Infectious Disease Panel Testing for Diagnosis of Infection in Different Body Sites: A Joint Report of the Association for Molecular Pathology, American Society for Microbiology, Infectious Diseases Society of America, and Pan American Society for Clinical Virology. The Journal of Molecular Diagnostics. 5. Naureckas Li C, Nakamura MM. 2022. Utility of Broad-Range PCR Sequencing for Infectious Diseases Clinical Decision Making: a Pediatric Center Experience. J Clin Microbiol 60:e0243721. 6. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, Leeflang MM, Sterne JA, Bossuyt PM, Group Q-. 2011. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 155:529-36. Liu J, Zhang Q, Dong YQ, Yin J, Qiu YQ. 2022. Diagnostic accuracy of metagenomic next-7. generation sequencing in diagnosing infectious diseases: a meta-analysis. Sci Rep 12:21032. 8. Eichenberger EM, Degner N, Scott ER, Ruffin F, Franzone J, Sharma-Kuinkel B, Shah P, Hong D, Dalai SC, Blair L, Hollemon D, Chang E, Ho C, Wanda L, de Vries C, Fowler VG, Ahmed AA. 2022.

354		Microbial Cell-Free DNA Identifies the Causative Pathogen in Infective Endocarditis and Remains
355		Detectable Longer Than Conventional Blood Culture in Patients with Prior Antibiotic Therapy.
356		Clin Infect Dis doi:10.1093/cid/ciac426.
357	9.	Dworsky ZD, Lee B, Ramchandar N, Rungvivatjarus T, Coufal NG, Bradley JS. 2022. Impact of Cell-
358		Free Next-Generation Sequencing on Management of Pediatric Complicated Pneumonia. Hosp
359		Pediatr 12:377-384.
360	10.	Brenner T, Skarabis A, Stevens P, Axnick J, Haug P, Grumaz S, Bruckner T, Luntz S, Witzke O, Pletz
361		MW, Ruprecht TM, Marschall U, Altin S, Greiner W, Berger MM, Group TICCT. 2021.
362		Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next
363		generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled,
364		interventional, open-label, multicenter trial. Trials 22:714.
365	11.	Han D, Li R, Shi J, Tan P, Zhang R, Li J. 2020. Liquid biopsy for infectious diseases: a focus on
366		microbial cell-free DNA sequencing. Theranostics 10:5501-5513.
367	12.	Blauwkamp TA, Thair S, Rosen MJ, Blair L, Lindner MS, Vilfan ID, Kawli T, Christians FC,
368		Venkatasubrahmanyam S, Wall GD, Cheung A, Rogers ZN, Meshulam-Simon G, Huijse L,
369		Balakrishnan S, Quinn JV, Hollemon D, Hong DK, Vaughn ML, Kertesz M, Bercovici S, Wilber JC,
370		Yang S. 2019. Analytical and clinical validation of a microbial cell-free DNA sequencing test for
371		infectious disease. Nat Microbiol 4:663-674.
372	13.	Rossoff J, Chaudhury S, Soneji M, Patel SJ, Kwon S, Armstrong A, Muller WJ. 2019. Noninvasive
373		Diagnosis of Infection Using Plasma Next-Generation Sequencing: A Single-Center Experience.
374		Open Forum Infect Dis 6.
375	14.	Benamu E, Gajurel K, Anderson JN, Lieb T, Gomez CA, Seng H, Aquino R, Hollemon D, Hong DK,
376		Blauwkamp TA, Kertesz M, Blair L, Bollyky PL, Medeiros BC, Coutre S, Zompi S, Montoya JG,

377		Deresinski S. 2021. Plasma Microbial Cell-free DNA Next Generation Sequencing in the Diagnosis
378		and Management of Febrile Neutropenia. Clin Infect Dis doi:10.1093/cid/ciab324.
379	15.	Yu J, Diaz JD, Goldstein SC, Patel RD, Varela JC, Reyenga C, Smith M, Smith T, Balls J, Ahmad S,
380		Mori S. 2021. Impact of Next-Generation Sequencing Cell-free Pathogen DNA Test on
381		Antimicrobial Management in Adults with Hematological Malignancies and Transplant
382		Recipients with Suspected Infections. Transplant Cell Ther doi:10.1016/j.jtct.2021.02.025.
383	16.	Francisco DMA, Woc-colburn L, Carlson TJ, Lasco T, Barrett MB, Mohajer MA. 2020. 680. The use
384		of plasma next-generation sequencing test in the management of immunocompetent and
385		immunocompromised patients – a single center retrospective study. Open Forum Infectious
386		Diseases 7:S393-S394.
387	17.	Hogan CA, Yang S, Garner OB, Green DA, Gomez CA, Dien Bard J, Pinsky BA, Banaei N. 2021.
388		Clinical Impact of Metagenomic Next-Generation Sequencing of Plasma Cell-Free DNA for the
389		Diagnosis of Infectious Diseases: A Multicenter Retrospective Cohort Study. Clin Infect Dis
390		72:239-245.
391	18.	Lee RA, Al Dhaheri F, Pollock NR, Sharma TS. 2020. Assessment of the Clinical Utility of Plasma
392		Metagenomic Next-Generation Sequencing in a Pediatric Hospital Population. J Clin Microbiol
393		58.
394	19.	Niles DT, Wijetunge DSS, Palazzi DL, Singh IR, Revell PA. 2020. Plasma Metagenomic Next-
395		Generation Sequencing Assay for Identifying Pathogens: a Retrospective Review of Test
396		Utilization in a Large Children's Hospital. J Clin Microbiol 58.
397	20.	National Center for Health Statistics (CDC). 2015. International Classification of Diseases, Tenth
398		Revision, Clinical Modification (ICD-10-CM).
399		https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Publications/ICD10CM/2022/icd10cm-tabular-
400		<u>2022-April-1.pdf</u> .

401	21.	Agency for Healthcare Research and Quality. October 2021. Clinical Classifications Software
402		Refined (CCSR). Healthcare Cost and Utilization Project (HCUP). Rockville, MD.
403		https://www.hcup-us.ahrq.gov/toolssoftware/ccsr/ccs_refined.jsp.
404	22.	Agency for Healthcare Research and Quality. July 2021. Immunocompromised State Diagnosis
405		and Procedure Codes.
406		https://qualityindicators.ahrq.gov/Downloads/Modules/PQI/V2021/TechSpecs/PQI_Appendix_C
407		<u>.pdf</u> .
408	23.	Agency for Healthcare Research and Quality. July 2021. Intermediate-Risk Immunocompromised
409		State Diagnosis Codes.
410		https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_G
411		<u>.pdf</u> .
412	24.	Agency for Healthcare Research and Quality. July 2021. High-Risk Immunocompromised State
413		Diagnosis and Procedure Codes.
413 414		Diagnosis and Procedure Codes. https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_F
414	25.	https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_F
414 415	25.	https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_Fpdf.
414 415 416	25.	https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_F .pdf. Blauwkamp TA, Ho C, Seng H, Hollemon D, Blair L, Yao JD, Warren D, Russell P, Davis T, Hong DK.
414 415 416 417	25.	https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_F .pdf. Blauwkamp TA, Ho C, Seng H, Hollemon D, Blair L, Yao JD, Warren D, Russell P, Davis T, Hong DK. 2019. Evaluation of Karius plasma next generation sequencing of microbial cell-free DNA to
414 415 416 417 418	25. 26.	https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_Fpdf. Blauwkamp TA, Ho C, Seng H, Hollemon D, Blair L, Yao JD, Warren D, Russell P, Davis T, Hong DK. 2019. Evaluation of Karius plasma next generation sequencing of microbial cell-free DNA to detect and quantitate Cytomegalovirus, Epstein-Barr Virus, and BK Virus, abstr American Society
414 415 416 417 418 419		https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI_Appendix_Fpdf. Blauwkamp TA, Ho C, Seng H, Hollemon D, Blair L, Yao JD, Warren D, Russell P, Davis T, Hong DK. 2019. Evaluation of Karius plasma next generation sequencing of microbial cell-free DNA to detect and quantitate Cytomegalovirus, Epstein-Barr Virus, and BK Virus, abstr American Society for Microbiology (ASM) Microbe 2019, San Francisco, CA,
414 415 416 417 418 419 420		https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI Appendix F.pdf. Blauwkamp TA, Ho C, Seng H, Hollemon D, Blair L, Yao JD, Warren D, Russell P, Davis T, Hong DK. 2019. Evaluation of Karius plasma next generation sequencing of microbial cell-free DNA to detect and quantitate Cytomegalovirus, Epstein-Barr Virus, and BK Virus, abstr American Society for Microbiology (ASM) Microbe 2019, San Francisco, CA, Fung M, Teraoka J, Lien K, Seng H, Parham A, Hollemon D, Hong DK, Blair L, Zompì S, Logan AC,
414 415 416 417 418 419 420 421		https://qualityindicators.ahrq.gov/Downloads/Modules/PDI/V2021/TechSpecs/PDI Appendix F.pdf. Blauwkamp TA, Ho C, Seng H, Hollemon D, Blair L, Yao JD, Warren D, Russell P, Davis T, Hong DK. 2019. Evaluation of Karius plasma next generation sequencing of microbial cell-free DNA to detect and quantitate Cytomegalovirus, Epstein-Barr Virus, and BK Virus, abstr American Society for Microbiology (ASM) Microbe 2019, San Francisco, CA, Fung M, Teraoka J, Lien K, Seng H, Parham A, Hollemon D, Hong DK, Blair L, Zompì S, Logan AC, Yao JD, Chin-Hong P. 2019. Use of the quantitative Karius® plasma next generation sequencing

425	27.	Relman DA, Falkow S, Ramakrishnan L. 2020. Chapter 1: A Molecular Perspective of Microbial
426		Pathogenicity, p 1-11. In Bennett JE, Bennett JE, Dolin R, Blaser MJ (ed), Mandell, Douglas, and
427		Bennett's principles and practice of infectious diseases, Ninth edition. ed, vol 1. Elsevier,
428		Philadelphia, PA.
429	28.	McKinney W. Data structures for statistical computing in python, abstr 9th Python in Science
430		Conference, Austin, TX, June 28 - July 3, 2010.
431	29.	Hunter J. 2007. Matplotlib: a 2D graphics environment. Computing in Science & Engineering.
432		9(3):90-95. doi:10.1109/MCSE.2007.55.
433	30.	Waskom M, Botvinnik O, O'Kane D, Hobson P, Lukauskas S, Gemperline DC, Augspurger T,
434		Halchenko Y, Cole JB, Warmenhoven J, de Ruiter J, Pye C, Hoyer S, Vanderplas J, Villalba S,
435		Kunter G, Quintero E, Bachant P, Martin M, Meyer K, Miles A, Ram Y, Yarkoni T, Williams ML,
436		Evans C, Fitzgerald C, B, Fonnesbeck C, Lee A, Qalieh A. 2017. mwaskom/seaborn: v0.8.1
437		(September 2017), September 3, 2017 ed doi:10.5281/zenodo.883859. Zenodo.
438	31.	Ahmed AA, Rosen M, Hong DK, Dalai SC, Macintyre A, Blair L, Lindner M, Balakrishnan S,
439		Bercovici S. Next-generation sequencing of pathogen cell-free DNA in plasma (Karius Test)
440		reveals Nocardia species diversity in clinical infections, abstr ASM Microbe, San Francisco, CA,
441		June 20-24, 2019.
442	32.	Smollin M, Lindner M, Blair L, Arun A, Degner N, Equils O, de Vries CR, Dalai SC, MacIntyre A,
443		Ahmed AA. Rapid, non-invasive detection of Legionella and Nocardia and resolution of species
444		diversity in clinical infections in immunocompromised hosts using the Karius Test, a plasma-
445		based microbial cell-free DNA sequencing test for pathogen identification, abstr 21st ICHS
446		Symposium, Melbourne, Australia, February 17-19, 2021.

447	33.	Graff K, Dominguez SR, Messacar K. 2021. Metagenomic Next-Generation Sequencing for
448		Diagnosis of Pediatric Meningitis and Encephalitis: A Review. J Pediatric Infect Dis Soc 10:S78-
449		S87.
450	34.	Haslam DB. 2021. Future Applications of Metagenomic Next-Generation Sequencing for
451		Infectious Diseases Diagnostics. J Pediatric Infect Dis Soc 10:S112-S117.
452	35.	Huang AL, Hendren N, Carter S, Larsen C, Garg S, La Hoz R, Farr M. 2022. Biomarker-Based
453		Assessment for Infectious Risk Before and After Heart Transplantation. Curr Heart Fail Rep
454		doi:10.1007/s11897-022-00556-z.
455	36.	Bergin SP, Chemaly R, Duttagupta R, Bigelow R, Dadwal S, Hill JA, Lee YJ, Haidar G, Luk A, Drelick
456		A, Chin-Hong PV, Benamu E, Davis T, Wolf O, McClain M, Maziarz E, Madut D, Bedoya A, Gilstrap
457		DL, Todd J, Barkauskas C, Spallone A, McDowell BJ, Small CB, Shariff D, Salsgiver E, Khawaja F,
458		Papanicolaou GA, Spagnoletti J, Van Besien K, English M, Fung M, Rusell P, Ibrahimi S, Pandey S,
459		Adams S, Liang W, Visweswaran A, Ho C, Nemirovich-Danchenko E, Braaten J, Sundermann L,
460		Mughar M, Chavez R, Romano R, Montgomery S, Kumar S, Dalai SC, Cho Y, Ahmed AA, et al.
461		2022. PICKUP: Pneumonia in the ImmunoCompromised - use of the Karius Test® for the
462		detection of Undiagnosed Pathogens abstr IDWeek 2022, Washington, D.C., October 20, 2022.
463	37.	Farnaes L, Wilke J, Ryan Loker K, Bradley JS, Cannavino CR, Hong DK, Pong A, Foley J, Coufal NG.
464		2019. Community-acquired pneumonia in children: cell-free plasma sequencing for diagnosis
465		and management. Diagn Microbiol Infect Dis 94:188-191.
466	38.	Eichenberger EM, de Vries CR, Ruffin F, Sharma-Kuinkel B, Park L, Hong D, Scott ER, Blair L,
467		Degner N, Hollemon DH, Blauwkamp TA, Ho C, Seng H, Shah P, Wanda L, Fowler VG, Ahmed AA.
468		2022. Microbial Cell-Free DNA Identifies Etiology of Bloodstream Infections, Persists Longer
469		Than Conventional Blood Cultures, and Its Duration of Detection Is Associated With Metastatic

470		Infection in Patients With Staphylococcus aureus and Gram-Negative Bacteremia. Clin Infect Dis
471		74:2020-2027.
472	39.	To RK, Ramchandar N, Gupta A, Pong A, Cannavino C, Foley J, Farnaes L, Coufal NG. 2021. Use of
473		Plasma Metagenomic Next-generation Sequencing for Pathogen Identification in Pediatric
474		Endocarditis. Pediatr Infect Dis J 40:486-488.
475	40.	de Melo Silva J, Pinheiro-Silva R, Dhyani A, Pontes GS. 2020. Cytomegalovirus and Epstein-Barr
476		Infections: Prevalence and Impact on Patients with Hematological Diseases. Biomed Res Int
477		2020:1627824.
478	41.	Hilt EE, Ferrieri P. 2022. Next Generation and Other Sequencing Technologies in Diagnostic
479		Microbiology and Infectious Diseases. Genes 13:1566.
480	42.	Vaca DJ, Dobler G, Fischer SF, Keller C, Konrad M, von Loewenich FD, Orenga S, Sapre SU, van
481		Belkum A, Kempf VAJ. 2022. Contemporary diagnostics for medically relevant fastidious
482		microorganisms belonging to the genera Anaplasma, Bartonella, Coxiella, Orientia, and
483		Rickettsia. FEMS Microbiol Rev doi:10.1093/femsre/fuac013.
484	43.	Haydour Q, Hage CA, Carmona EM, Epelbaum O, Evans SE, Gabe LM, Knox KS, Kolls JK,
485		Wengenack NL, Prokop LJ, Limper AH, Murad MH. 2019. Diagnosis of Fungal Infections. A
486		Systematic Review and Meta-Analysis Supporting American Thoracic Society Practice Guideline.
487		Ann Am Thorac Soc 16:1179-1188.
488	44.	Centers for Disease Control and Prevention (CDC). Tracking Candida auris.
489		https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html. Accessed December 15, 2022.
490	45.	Lockhart SR, Toda M, Benedict K, Caceres DH, Litvintseva AP. 2021. Endemic and Other
491		Dimorphic Mycoses in The Americas. J Fungi (Basel) 7.

492	46.	Centers for Disease Control and Prevention (CDC). C. gattii Infection Statistics.
493		https://www.cdc.gov/fungal/diseases/cryptococcosis-gattii/statistics.html. Accessed June 5,
494		2022.
495	47.	Yu VL, Plouffe JF, Pastoris MC, Stout JE, Schousboe M, Widmer A, Summersgill J, File T, Heath
496		CM, Paterson DL, Chereshsky A. 2002. Distribution of Legionella species and serogroups isolated
497		by culture in patients with sporadic community-acquired legionellosis: an international
498		collaborative survey. J Infect Dis 186:127-8.
499	48.	Helbig JH, Uldum SA, Bernander S, Luck PC, Wewalka G, Abraham B, Gaia V, Harrison TG. 2003.
500		Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-
501		associated, and nosocomial legionnaires' disease. J Clin Microbiol 41:838-40.
502	49.	Fields BS, Benson RF, Besser RE. 2002. Legionella and Legionnaires' disease: 25 years of
503		investigation. Clin Microbiol Rev 15:506-26.
504	50.	Phin N, Parry-Ford F, Harrison T, Stagg HR, Zhang N, Kumar K, Lortholary O, Zumla A, Abubakar I.
505		2014. Epidemiology and clinical management of Legionnaires' disease. Lancet Infect Dis
506		14:1011-21.
507	51.	CLSI. 2018. Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp.,
508		and Other Aerobic Actinomycetes. In (ed), CLSI Supplement M62. Clinical and Laboratory
509		Standards Institute, Wayne, PA.
510	52.	Sax H, Bloemberg G, Hasse B, Sommerstein R, Kohler P, Achermann Y, Rossle M, Falk V, Kuster
511		SP, Bottger EC, Weber R. 2015. Prolonged Outbreak of Mycobacterium chimaera Infection After
512		Open-Chest Heart Surgery. Clin Infect Dis 61:67-75.
513	53.	Pollock NR, MacIntyre AT, Blauwkamp TA, Blair L, Ho C, Calderon R, Franke MF. 2021. Detection
514		of Mycobacterium tuberculosis cell-free DNA to diagnose TB in pediatric and adult patients. Int J
515		Tuberc Lung Dis 25:403-405.

516	54.	Goldberg B, Sichtig H, Geyer C, Ledeboer N, Weinstock GM. 2015. Making the Leap from
517		Research Laboratory to Clinic: Challenges and Opportunities for Next-Generation Sequencing in
518		Infectious Disease Diagnostics. mBio 6:e01888-15.
519	55.	Simner PJ, Miller S, Carroll KC. 2018. Understanding the Promises and Hurdles of Metagenomic
520		Next-Generation Sequencing as a Diagnostic Tool for Infectious Diseases. Clin Infect Dis 66:778-
521		788.
522	56.	Wright WF, Simner PJ, Carroll KC, Auwaerter PG. 2022. Progress Report: Next-Generation
523		Sequencing, Multiplex Polymerase Chain Reaction, and Broad-Range Molecular Assays as
524		Diagnostic Tools for Fever of Unknown Origin Investigations in Adults. Clin Infect Dis 74:924-932.
525	57.	Steensels D, Verhaegen J, Lagrou K. 2011. Matrix-assisted laser desorption ionization-time of
526		flight mass spectrometry for the identification of bacteria and yeasts in a clinical microbiological
527		laboratory: a review. Acta Clin Belg 66:267-73.
528	58.	Camargo JF, Ahmed AA, Lindner MS, Morris MI, Anjan S, Anderson AD, Prado CE, Dalai SC,
529		Martinez OV, Komanduri KV. 2019. Next-generation sequencing of microbial cell-free DNA for
530		rapid noninvasive diagnosis of infectious diseases in immunocompromised hosts. F1000Res
531		8:1194.
532	59.	Edward P, Handel AS. 2021. Metagenomic Next-Generation Sequencing for Infectious Disease
533		Diagnosis: A Review of the Literature With a Focus on Pediatrics. J Pediatric Infect Dis Soc
534		10:S71-S77.
535	60.	Fishman JA. 2022. Approach to the immunocompromised patient with fever and pulmonary
536		infiltrates. In Blumberg EA, Bond S (ed), UptoDate, Waltham, MA.
537	61.	Pierce KK. 2013. Chapter 40 - Immunocompromised Host, p 277-292. <i>In</i> Parsons PE, Wiener-
538		Kronish JP (ed), Critical Care Secrets (Fifth Edition) doi: https://doi.org/10.1016/B978-0-323-
539		<u>08500-7.00041-2</u> . Mosby.



563 68. Brown-Elliott BA, Wallace J, Richard J. February 2019. Mycobacterium: clinical and laboratory 564 characteristics of rapidly growing mycobacteria. In Carroll KC, Pfaller MA, Landry ML, McAdam 565 AJ, Patel R, Richter SS, Warnock DW (ed), Manual of Clinical Microbiology, 12th ed. ASM Press. 566 69. Centers for Disease Control and Prevention (CDC). 2022 National Notifiable Infectious Diseases. 567 https://ndc.services.cdc.gov/search-results-year/. Accessed March 1, 2022. 568 70. Hoffmann K, Pawlowska J, Walther G, Wrzosek M, de Hoog GS, Benny GL, Kirk PM, Voigt K. 569 2013. The family structure of the Mucorales: a synoptic revision based on comprehensive 570 multigene-genealogies. Persoonia 30:57-76. 571

Table 1. Plasma mcfDNA sequencing test performance metrics in production, April 2018-end of

September 2021.

572

573

574

575

576

577

Metric	Production ¹	Validation ²
Sample acceptance rate	98%	98%
Total yield	96%	98%
First pass yield	91%	91%
Results delivered next operational day	90%	90%

¹Based on 20,087 clinical samples received during this study.

²Based on 2,000 clinical samples tested as part of the initial Karius Test validation study (12)

Table 2. ICD10 codes by principal diagnosis type for those patients with ICD10 codes indicated on Karius TRFs (N=4,423), April 2018–September 2021.

Total	IC	Fever	Sepsis
68			
1437		722	
800			
580	288		
543	47		231
485	320		
416			
290	140		
259	9		
242			
	68 1437 800 580 543 485 416 290 259	68 1437 800 580 288 543 47 485 320 416 290 140 259 9	68 1437 722 800 288 580 288 543 47 485 320 416 290 259 9

Digestive system diseases	162	21		
Skin diseases	111			
Genitourinary system diseases	101	15		
Endocrine/metabolic diseases	91	4		
Injury, poisoning, external causes	83	25		
Congenital malformations	76			
Codes for special purposes	20			
Eye/adnexa diseases	16			
Mental/behavioral disorders	13			
Ear/mastoid diseases	7			
Pregnancy/childbirth	7			
External causes of morbidity	3			
Total number of patients by diagnosis chapter	5810	869	722	231

TRF = test report form. IC = immunocompromised. Fever: any ICD10 starting with "R50"; sepsis: any ICD10 starting with "A41"; IC: any ICD10 annotated as immunocompromised from AHRQ code list. Each TRF could contain up to 2 ICD10 codes, and each patient had between 1–5 unique ICD10 codes. For the study period, there were 15,165 patients with a positive or negative report (18,690 reports).

Table 3. Top 50 taxa detected by sorted microorganism group (bacteria, fungi, and viruses) and then alphabetically by taxon name with number detected and median and IQR of molecules/μl (MPM) values for each taxon, April 2018–September 2021.

Taxon name	Number	Median (MPM)	IQR (MPM)
	detected		
Bacteria			
Acinetobacter haemolyticus	199	142.97	192.68
Bacteroides fragilis	217	264.74	1,046.15
Bacteroides ovatus	133	141.43	476.14
Bacteroides thetaiotaomicron	146	221.79	742.60
Bacteroides vulgatus	392	153.01	413.32
Enterobacter cloacae complex	343	821.34	6,742.30
Enterococcus faecalis	582	617.90	3,285.15
Enterococcus faecium	510	687.63	3,958.33
Escherichia coli	1088	684.92	3,623.17
Fusobacterium nucleatum	299	460.25	1,922.08
Haemophilus influenzae	288	157.09	425.59
Haemophilus parainfluenzae	178	284.92	1,121.19
Helicobacter pylori	207	217.44	601.83
Klebsiella pneumoniae	501	910.19	5,889.84
Lactobacillus fermentum	165	256.13	1,058.08
Lactobacillus rhamnosus	281	344.33	1,250.14
Prevotella melaninogenica	509	208.52	545.66

Prevotella oris	170	517.78	2,094.07
Pseudomonas aeruginosa	817	1,005.18	6,874.18
Rothia dentocariosa	110	117.02	256.72
Rothia mucilaginosa	454	177.53	369.36
Serratia marcescens	99	492.72	2,956.54
Staphylococcus aureus	561	838.21	5,665.43
Staphylococcus epidermidis	716	579.58	2,689.68
Staphylococcus haemolyticus	92	1,137.08	5,450.01
Stenotrophomonas maltophilia	169	1,983.18	11,864.14
Streptococcus intermedius	100	354.95	1,048.47
Streptococcus mitis	356	226.15	897.48
Streptococcus oralis	140	235.54	730.42
Streptococcus parasanguinis	186	152.35	298.03
Streptococcus pneumoniae	214	975.48	11,933.10
Streptococcus pyogenes	95	1,064.08	9,773.54
Streptococcus salivarius	104	253.73	799.10
Streptococcus thermophilus	184	190.84	339.33
Veillonella dispar	162	140.88	269.85
Veillonella parvula	256	202.30	476.57
Fungi			
Aspergillus fumigatus	186	300.10	723.60
Candida albicans	260	624.63	2,074.97
Candida glabrata	113	611.85	1,449.20
	1		

Candida tropicalis	103	784.49	3,997.85
Pneumocystis jiroveci	258	2,452.78	18,084.89
Viruses		·	
BK polyomavirus	354	472.38	2,677.18
Cytomegalovirus	1275	633.93	3,889.67
Epstein-Barr virus	902	272.34	852.32
Herpes simplex virus type 1	479	754.78	3,208.06
Human herpesvirus 6B	468	518.74	3,268.72
Human herpesvirus 7	98	82.74	342.37
Human adenovirus B	100	3,184.75	69,714.71
Human adenovirus C	171	573.87	10,160.48
Torque teno virus	135	484.19	1,935.97

Figure Captions

- **Fig. 1.** Number of detections by the Karius test of the different super groups of taxa, Apr 2018–Sept 2021, N=22,792: bacteria, 16,221; viruses, 4,737; fungi, 1,758; and parasites, 70. Percentages reflect proportion of total number of detections spanning 701 microbial taxa.
- **Fig. 2.** Number of detected taxa counts per report for all positive reports, Apr 2018–Sept 2021. Percentages reflect the proportion of all positive reports (N=10,752).
- **Fig. 3.** Frequency distribution of *Legionella*-like organisms detected, n=80 (<1% of all bacterial detections, N=16,203), Apr 2018–Sept 2021.
- **Fig. 4.** Frequency distribution of *Nocardia* spp. detections, n=76 (<1% bacterial detections, N=16,203), Apr 2018–Sept 2021. *Indicates species more frequently isolated from clinical specimens (66). †Indicates species-specific susceptibility patterns (51)
- **Fig. 5.** Frequency distribution of *Mycobacterium* spp. detections, n=156 (1% of all bacterial detections, N=16,203), Apr 2018–Sept 2021. *Indicates slowly growing mycobacteria of established clinical significance (67). †Indicates rapidly growing mycobacteria considered common human pathogens. ‡Indicates rapidly growing mycobacteria considered less common or rare human pathogens (68).
- **Fig. 6.** Frequency distribution of zoonotic and vector borne bacteria detections, n=247 (2% of all bacterial detections, N=16,203), Apr 2018–Sept 2021. *Indicates bacteria causing a nationally notifiable infectious disease (69).
- **Fig. 7.** Frequency distribution of *Candida* spp. detections, n=648 (36% of all fungal detections, N=1,776), Apr 2018–Sept 2021.
- **Fig. 8.** Frequency distribution of *Aspergillus* spp. detections, n=374 (21% of all fungal detections, n=1,776), Apr 2018–Sept 2021. *Indicates most common pathogenic species.
- **Fig 9.** Frequency distribution of detections in the order *Mucorales*, n=196 (11% of all fungal detections, N=1,776), Apr 2018–Sept 2021. *Indicates taxa implicated in human mucormycosis (70).

- **Fig 10.** Frequency distribution of detections of systemic dimorphic fungi, n=78 (4% of all fungal detections, N=1,776), Apr 2018–Sept 2021.
- **Fig 11.** Frequency distribution of detections of dematiaceous fungi, n=33 (2% of all fungal detections, N=1,776), Apr 2018–Sept 2021.
- **Fig 12.** Frequency distribution of detections of protozoan parasites, n=57 (89% of all eukaryotic parasite detections, N=64), Apr 2018–Sept 2021.

Supplemental Table 1. All 701 taxa detected in reports with number detected and median and interquartile range for quantification in molecules/ μ l (MPM) for each taxon, Apr 2018–Sept 2021. The top 50 detected are highlighted in **bold**.

Taxa name	Number	Median	IQR
	detected	МРМ	
Abiotrophia defectiva	17	123.78	299.60
Acanthamoeba	1	12,186.93	0.00
Acetobacter nitrogenifigens	2	168.78	20.74
Achromobacter insolitus	1	37,178.62	0.00
Achromobacter ruhlandii	6	482.95	1,836.01
Achromobacter xylosoxidans	32	689.96	2,977.61
Acidaminococcus intestini	10	440.20	634.82
Acidovorax citrulli	2	53,316.31	37,869.12
Acinetobacter baumannii	27	289.72	809.16
Acinetobacter bereziniae	1	441.41	0.00
Acinetobacter haemolyticus	199	142.97	192.68
Acinetobacter nosocomialis	2	37.02	12.10
Acinetobacter pittii	10	419.25	1,648.00
Acinetobacter radioresistens	3	53.56	207.40
Acinetobacter soli	2	142.97	58.05
Acinetobacter ursingii	8	122.31	205.92
Actinomyces europaeus	1	54.51	0.00
Actinomyces gerencseriae	1	1,318.27	0.00

39	145.47	205.79
10	89.85	180.58
1	82.41	0.00
4	2,279.05	25,827.25
32	87.49	162.81
25	134.56	124.41
2	346.60	212.30
45	87.93	98.10
25	1,611.82	9,610.65
2	466.47	402.10
2	3,266.81	2,733.34
2	61.26	36.48
13	69.51	84.93
1	197.69	0.00
15	1,841.34	23,328.59
29	1,041.16	18,934.90
24	664.17	1,392.99
7	123.86	41.69
5	113.08	83.54
4	14,786.35	29,889.21
11	142.47	315.88
1	106.86	0.00
1	86.80	0.00
	10 1 4 32 25 2 45 2 2 2 13 1 15 29 24 7 5 4 11 1	10 89.85 1 82.41 4 2,279.05 32 87.49 25 134.56 2 346.60 45 87.93 25 1,611.82 2 466.47 2 3,266.81 2 61.26 13 69.51 1 197.69 15 1,841.34 29 1,041.16 24 664.17 7 123.86 5 113.08 4 14,786.35 11 142.47 1 106.86

Anaerococcus hydrogenalis	2	763.57	645.00
Anaerococcus lactolyticus	2	495.87	213.92
Anaerococcus prevotii	2	72.70	27.37
Anaerococcus tetradius	3	2,981.82	1,234.60
Anaeroglobus geminatus	8	283.70	351.35
Anaerostipes caccae	5	963.17	458.19
Anaplasma phagocytophilum	6	27,154.21	120,865.63
Anncaliia algerae	1	117,297.14	0.00
Arcanobacterium haemolyticum	1	192.25	0.00
Aspergillus calidoustus	17	264.07	753.65
Aspergillus chevalieri	2	36.04	12.13
Aspergillus flavus	54	543.15	2,437.50
Aspergillus fumigatus	186	300.10	723.60
Aspergillus glaucus	3	64.01	25.74
Aspergillus glaucus Aspergillus lentulus	3	5,783.25	4,067.74
Aspergillus lentulus	3	5,783.25	4,067.74
Aspergillus lentulus Aspergillus luchuensis	3	5,783.25	4,067.74 92,159.37
Aspergillus lentulus Aspergillus luchuensis Aspergillus niger	3 3 23	5,783.25 108.15 150.50	4,067.74 92,159.37 403.84
Aspergillus lentulus Aspergillus luchuensis Aspergillus niger Aspergillus nomiae	3 3 23 1	5,783.25 108.15 150.50 85.74	4,067.74 92,159.37 403.84 0.00
Aspergillus lentulus Aspergillus luchuensis Aspergillus niger Aspergillus nomiae Aspergillus nomius	3 3 23 1	5,783.25 108.15 150.50 85.74 387.11	4,067.74 92,159.37 403.84 0.00
Aspergillus lentulus Aspergillus luchuensis Aspergillus niger Aspergillus nomiae Aspergillus nomius Aspergillus novofumigatus	3 3 23 1 1	5,783.25 108.15 150.50 85.74 387.11 214.80	4,067.74 92,159.37 403.84 0.00 0.00
Aspergillus lentulus Aspergillus luchuensis Aspergillus niger Aspergillus nomiae Aspergillus nomius Aspergillus novofumigatus Aspergillus oryzae	3 3 23 1 1 1 41	5,783.25 108.15 150.50 85.74 387.11 214.80 349.37	4,067.74 92,159.37 403.84 0.00 0.00 1,739.82

Aspergillus sydowii	3	80.90	16.85
Aspergillus terreus	12	399.25	1,965.25
Aspergillus thermomutatus	1	15.53	0.00
Aspergillus tubingensis	16	576.23	8,260.64
Aspergillus udagawae	3	48.37	103.09
Atopobium parvulum	18	122.20	203.85
Atopobium rimae	5	352.99	869.84
Atopobium vaginae	11	411.66	499.92
Aureobasidium melanogenum	1	13.31	0.00
Aureobasidium pullulans	3	336.28	947.39
Aureobasidium subglaciale	1	1,247.08	0.00
Babesia microti	1	162,139.56	0.00
Bacillus cereus	51	926.50	10,719.62
Bacillus coagulans	1	150.16	0.00
Bacillus licheniformis	1	73.56	0.00
Bacillus megaterium	1	144.20	0.00
Bacillus subtilis	1	75.10	0.00
Bacillus thuringiensis	11	358.99	3,434.89
Bacteroides caccae	52	98.68	308.62
Bacteroides distasonis	80	141.94	297.31
Bacteroides eggerthii	4	370.01	662.35
Bacteroides faecis	17	264.41	1,469.41
Bacteroides forsythus	2	50.32	0.95

Bacteroides fragilis	217	264.74	1,046.15
Bacteroides merdae	31	111.12	134.39
Bacteroides ovatus	133	141.43	476.14
Bacteroides pyogenes	2	132.40	13.83
Bacteroides salyersiae	2	4,234.08	2,497.91
Bacteroides stercoris	36	113.62	186.94
Bacteroides thetaiotaomicron	146	221.79	742.60
Bacteroides uniformis	90	182.90	380.86
Bacteroides vulgatus	392	153.01	413.32
Balamuthia mandrillaris	1	99.03	0.00
Bartonella clarridgeiae	3	759.52	2,412.20
Bartonella henselae	90	2,912.27	15,938.61
Bartonella quintana	5	36,551.67	40,236.66
Bartonella vinsonii	2	13,357.39	13,293.11
Bergeyella zoohelcum	1	113.67	0.00
Bifidobacterium adolescentis	1	54.54	0.00
Bifidobacterium animalis	4	155.74	138.28
Bifidobacterium breve	26	285.78	3,313.08
Bifidobacterium dentium	3	65.97	108.26
Bifidobacterium longum	39	196.50	457.04
Bifidobacterium scardovii	2	118.98	83.45
Bipolaris papendorfii	1	2,432.40	0.00
BK polyomavirus	354	472.38	2,677.18
		1	

Blastomyces dermatitidis	10	848.96	1,341.24
Bordetella bronchiseptica	2	4,526.17	4,177.42
Bordetella hinzii	1	128.84	0.00
Bordetella pertussis	2	92.47	43.01
Bordetella trematum	1	76.35	0.00
Borrelia burgdorferi	1	195.35	0.00
Borrelia hermsii	1	988.13	0.00
Brachyspira pilosicoli	1	92.04	0.00
Brevibacterium casei	10	131.21	284.45
Brevundimonas diminuta	3	132.30	392.15
Brucella melitensis	5	373.73	386.84
Bulleidia extructa	3	271.01	197.25
Burkholderia ambifaria	2	909.75	831.71
Burkholderia anthina	1	108.71	0.00
Burkholderia cenocepacia	4	233.10	667.72
Burkholderia cepacia	6	319.85	569.70
Burkholderia cepacia complex	46	105.98	270.69
Burkholderia contaminans	7	78.48	47.62
Burkholderia gladioli	5	136.42	160.50
Burkholderia multivorans	14	108.65	397.76
Campylobacter coli	1	550.26	0.00
Campylobacter concisus	27	203.89	336.72
Campylobacter curvus	4	159.86	213.02

Campylobacter fetus	3	398.01	1,838.80
Campylobacter gracilis	4	91.15	144.24
Campylobacter jejuni	6	230.28	219.37
Campylobacter showae	8	320.77	351.41
Campylobacter upsaliensis	2	69.79	19.83
Campylobacter ureolyticus	6	110.70	380.34
Candida albicans	260	624.63	2,074.97
Candida carpophila	5	15,987.23	22,145.87
Candida dubliniensis	38	1,130.01	2,173.12
Candida glabrata	113	611.85	1,449.20
Candida kefyr	4	195.64	1,330.87
Candida krusei	17	2,806.67	26,774.01
Candida lusitaniae	5	840.07	645.34
Candida orthopsilosis	5	3,068.99	10,092.36
Candida parapsilosis	72	447.94	2,020.79
Candida tropicalis	103	784.49	3,997.85
Candida utilis	4	147.35	47.24
Capnocytophaga canimorsus	6	3,404.20	9,150.42
Capnocytophaga gingivalis	13	139.37	206.78
Capnocytophaga granulosa	1	304.45	0.00
Capnocytophaga ochracea	3	433.17	372.25
Capnocytophaga sputigena	15	95.80	296.68
Cardiobacterium hominis	26	8,419.91	23,662.49
			1

Cellulomonas flavigena	4	87.77	83.74
Chimpanzee alpha-1 herpesvirus	3	6,380.71	15,691.54
Chlamydia pneumoniae	1	185.79	0.00
Chlamydia trachomatis	2	94.87	43.63
Chlamydophila pneumoniae	1	178.58	0.00
Chromobacterium haemolyticum	1	670.28	0.00
Chryseobacterium indologenes	2	846.11	538.86
Citrobacter amalonaticus	12	128.09	1,209.45
Citrobacter braakii	9	317.67	550.18
Citrobacter freundii	48	318.96	2,449.89
Citrobacter koseri	20	2,213.27	8,786.56
Cladophialophora bantiana	3	65.05	105.91
Clavispora lusitaniae (Candida lusitaniae)	4	2,031.99	6,036.17
Clostridioides difficile (Clostridium difficile)	10	418.00	1,377.85
Clostridium baratii	3	63.89	31.30
Clostridium bifermentans	1	12,394.39	0.00
Clostridium butyricum	14	359.16	1,482.07
Clostridium cadaveris	2	134,104.38	133,713.96
Clostridium clostridioforme	23	168.39	149.54
Clostridium difficile	11	359.74	839.88
Clostridium hylemonae	3	248.36	720.76
Clostridium innocuum	81	199.92	359.57
Clostridium neonatale	12	213.37	209.89

Clostridium novyi	1	2,231.87	0.00
Clostridium paraputrificum	8	113.22	379.46
Clostridium perfringens	25	145.68	3,153.06
Clostridium sordellii	2	399.72	333.56
Clostridium ventriculi	8	313.30	1,235.18
Coccidioides immitis	14	136.76	113.94
Coccidioides posadasii	4	179.60	828.91
Comamonas kerstersii	1	47.81	0.00
Comamonas testosteroni	1	3,272.81	0.00
Conidiobolus incongruus	1	48.23	0.00
Corynebacterium accolens	2	64.43	43.63
Corynebacterium afermentans	9	98.51	75.43
Corynebacterium amycolatum	27	496.48	809.76
Corynebacterium aurimucosum	13	81.42	136.10
Corynebacterium diphtheriae	3	4,891.94	3,193.06
Corynebacterium freneyi	1	47.98	0.00
Corynebacterium jeikeium	16	625.78	1,064.80
Corynebacterium kroppenstedtii	7	100.38	428.77
Corynebacterium massiliense	3	70.34	909.02
Corynebacterium matruchotii	6	127.24	247.41
Corynebacterium minutissimum	2	89.98	32.45
Corynebacterium propinquum	11	324.85	832.56
Corynebacterium pseudodiphtheriticum	2	12,671.39	12,436.87
	1		

Corynebacterium riegelii	1	423.76	0.00
Corynebacterium striatum	40	844.16	1,833.64
Corynebacterium urealyticum	2	382.25	270.50
Corynebacterium ureicelerivorans	1	358.20	0.00
Corynebacterium xerosis	1	36.10	0.00
Coxiella burnetii	10	1,059.25	6,607.37
Cronobacter sakazakii (Enterobacter sakazakii)	3	238.87	9,741.76
Cryptococcus gattii VGIII (Cryptococcus	1	170.32	0.00
bacillisporus)			
Cryptococcus neoformans	6	618.88	748.02
Cryptosporidium hominis	1	26.58	0.00
Cryptosporidium parvum	2	502.43	33.62
Cunninghamella	17	2,125.97	5,735.88
Cupriavidus gilardii	1	7,409.84	0.00
Cupriavidus metallidurans	4	118.73	133.91
Curvularia lunata	2	1,038.94	938.16
Curvularia papendorfii (Bipolaris papendorfii)	1	364.16	0.00
Cutibacterium granulosum (Propionibacterium	1	430.63	0.00
granulosum)			
Cyberlindnera fabianii (Hansenula fabianii)	1	826.61	0.00
Cyberlindnera jadinii (Candida utilis)	1	47.54	0.00
Cyclospora cayetanensis	1	34,376.00	0.00
Cytomegalovirus (CMV)	1275	633.93	3,889.67

Delftia acidovorans	3	145.56	656.29
Dermacoccus nishinomiyaensis	12	215.47	245.46
Dialister micraerophilus	1	3,320.59	0.00
Dysgonomonas capnocytophagoides	2	1,105.81	879.71
Dysgonomonas mossii	2	3,397.16	2,953.55
Echinococcus multilocularis	2	365.15	10.57
Eggerthella lenta	5	361.83	768.91
Ehrlichia chaffeensis	15	638,224.07	27,830,155.73
Ehrlichia muris	1	167,462.89	0.00
Eikenella corrodens	11	197.05	345.79
Elizabethkingia anophelis	3	1,740.10	1,595.66
Encephalitozoon cuniculi	1	138.90	0.00
Encephalitozoon hellem	1	738.90	0.00
Entamoeba histolytica	4	217.00	177.36
Enterobacter aerogenes	18	582.41	1,517.71
Enterobacter cloacae complex	343	821.34	6,742.30
Enterobacter sakazakii	1	69.47	0.00
Clostridium clostridioforme	26	228.09	873.58
Enterococcus avium	34	321.64	2,834.41
Enterococcus casseliflavus	12	80.85	717.36
Enterococcus cecorum	2	24.05	0.14
Enterococcus durans	11	1,163.27	5,902.22
Enterococcus faecalis	582	617.90	3,285.15

Enterococcus faecium	510	687.63	3,958.33
Enterococcus gallinarum	42	498.60	1,084.89
Enterococcus gilvus	1	14.74	0.00
Enterococcus hirae	1	2,013.10	0.00
Enterococcus italicus	1	22.57	0.00
Enterococcus mundtii	3	110.99	313.15
Enterococcus raffinosus	21	760.91	8,028.00
Enterococcus saccharolyticus	1	22.43	0.00
Enterocytozoon bieneusi	5	4,069.52	4,182.75
Epstein-Barr virus (EBV)	902	272.34	852.32
Erwinia billingiae	1	363.57	0.00
Erysipelothrix rhusiopathiae	2	112.31	46.47
Escherichia albertii	1	680.08	0.00
Escherichia coli	1088	684.92	3,623.17
Eubacterium limosum	3	161.41	3,525.21
Eubacterium nodatum	4	414.98	459.34
Exophiala dermatitidis	3	15,333.38	43,020.90
Exophiala oligosperma	1	120.68	0.00
Exophiala sideris	1	53.15	0.00
Exophiala xenobiotica	2	107.22	44.29
Fenollaria massiliensis	1	92.90	0.00
Filifactor alocis	11	180.11	503.01
Filobasidium wieringae	1	1,067.05	0.00
		ı	<u> </u>

Finegoldia magna	10	66.60	154.12
Fluoribacter bozemanae (Legionella bozemanae)	5	696.51	172.05
Francisella tularensis	5	1,300.91	3,708.73
Fusarium euwallaceae	3	146.05	2,243.26
Fusarium fujikuroi	1	1,197.99	0.00
Fusarium graminearum	1	24.47	0.00
Fusarium oxysporum	3	424.38	612.34
Fusarium proliferatum	5	55.47	34.81
Fusarium solani	6	205.17	150.05
Fusobacterium mortiferum	7	462.67	2,476.66
Fusobacterium necrophorum	38	3,678.24	26,778.68
Fusobacterium nucleatum	299	460.25	1,922.08
Fusobacterium periodonticum	34	178.91	241.99
Fusobacterium ulcerans	5	55.62	49.69
Fusobacterium varium	2	49.18	23.25
Gardnerella vaginalis	34	138.12	203.18
Gemella bergeri	6	76,955.37	452,814.11
Gemella haemolysans	32	178.44	316.61
Gemella morbillorum	15	215.69	845.80
Gemella sanguinis	8	163.63	721.34
Gleimia europaea (Actinomyces europaeus)	2	103.94	33.67
Gordonia aichiensis	1	65.41	0.00
Gordonia bronchialis	6	219.80	71.67

Gordonia terrae	1	25.50	0.00
Granulicatella adiacens	34	273.92	1,115.83
Granulicatella elegans	4	169.28	252.13
Graphilbum fragrans	1	65.53	0.00
Haemophilus haemolyticus	23	205.44	720.41
Haemophilus influenzae	288	157.09	425.59
Haemophilus parahaemolyticus	9	184.28	338.82
Haemophilus parainfluenzae	178	284.92	1,121.19
Haemophilus quentini	11	125.14	219.98
Haemophilus sputorum	1	331.33	0.00
Hafnia paralvei	6	13,126.59	26,361.30
Helicobacter bilis	10	293.61	119.67
Helicobacter cinaedi	11	116.73	113.48
Helicobacter fennelliae	2	130.12	41.01
Helicobacter magdeburgensis	5	133.98	748.86
Helicobacter pylori	207	217.44	601.83
Herpes simplex virus type 1 (HSV-1)	479	754.78	3,208.06
Herpes simplex virus type 2 (HSV-2)	86	324.72	2,900.39
Histoplasma capsulatum	43	2,614.46	22,781.42
Human adenovirus A	30	3,030.46	31,375.54
Human adenovirus B	100	3,184.75	69,714.71
Human adenovirus C	171	573.87	10,160.48
Human adenovirus D	26	451.67	1,427.75

Human adenovirus E	1	107,282.84	0.00
Human bocavirus	29	1,220.78	5,360.88
Human herpesvirus 6A	54	182.72	697.25
Human herpesvirus 6B	468	518.74	3,268.72
Human herpesvirus 7	98	82.74	342.37
Human papillomavirus 2	2	47.34	3.09
Human parvovirus	5	239.40	2,068.01
Human parvovirus B19	11	8,084.47	15,721.03
Human polyomavirus 6	25	122.57	278.60
Human polyomavirus 7	8	269.11	681.14
Janibacter indicus	5	129.90	42.67
JC polyomavirus	52	224.82	417.80
Kaposi sarcoma-associated herpesvirus	42	593.21	4,796.06
KI polyomavirus	4	1,975.32	5,069.99
Kingella denitrificans	3	79.66	60.33
Kingella kingae	18	180.36	297.50
Klebsiella aerogenes	22	184.60	926.18
Klebsiella aerogenes (Enterobacter aerogenes)	45	3,056.44	6,026.75
Klebsiella michiganensis	53	1,210.50	10,222.36
Klebsiella oxytoca	31	542.85	2,449.33
Klebsiella pneumoniae	501	910.19	5,889.84
Klebsiella quasipneumoniae	32	431.21	12,757.58
Klebsiella variicola	56	655.76	4,440.31

Kluyvera ascorbata	2	258.18	136.69
Kluyvera cryocrescens	2	126.26	113.58
Kluyveromyces marxianus (Candida kefyr)	5	708.32	6,149.77
Kocuria kristinae	1	188.97	0.00
Kocuria rhizophila	9	114.18	742.54
Kytococcus sedentarius	15	131.57	375.38
Lactobacillus acidophilus	25	285.46	2,591.23
Lactobacillus casei	71	426.98	1,772.48
Lactobacillus crispatus	23	239.98	332.32
Lactobacillus fermentum	165	256.13	1,058.08
Lactobacillus gasseri	89	295.93	1,023.59
Lactobacillus iners	8	210.70	1,157.73
Lactobacillus jensenii	8	418.21	2,797.12
Lactobacillus plantarum	18	187.50	707.49
Lactobacillus rhamnosus	281	344.33	1,250.14
Lactobacillus sakei	2	97.72	76.11
Lactobacillus ultunensis	3	98.39	53.35
Lactococcus garvieae	1	52.98	0.00
Lawsonella clevelandensis	2	715.24	169.78
Leclercia adecarboxylata	2	80.78	37.28
Legionella anisa	3	2,719.09	2,035.94
Legionella bozemanae	1	396,695.61	0.00
Legionella bozemaniae	3	391.47	418,155.06

Legionella brunensis	1	400.54	0.00
Legionella cincinnatiensis	1	76.45	0.00
Legionella feeleii	6	1,093.57	7,557.04
Legionella hackeliae	1	270.00	0.00
Legionella jordanis	1	1,330.26	0.00
Legionella longbeachae	6	1,234.99	3,502.14
Legionella maceachernii	7	4,043.52	6,027.02
Legionella micdadei	3	14,462.63	12,364.41
Legionella pneumophila	33	3,071.64	70,034.47
Legionella sainthelensi	3	24,516.11	1,247,656.68
Legionella tunisiensis	1	76,444.86	0.00
Leishmania panamensis	1	3,351.42	0.00
Lelliottia amnigena (Enterobacter amnigenus)	1	34.22	0.00
Leptospira borgpetersenii	1	40.53	0.00
Leptospira interrogans	4	3,951.60	4,351.77
Leptospira kirschneri	6	837.62	244.70
Leptospira noguchii	1	382.24	0.00
Leptospira santarosai	2	331.11	47.28
Leptotrichia buccalis	1	578.89	0.00
Leptotrichia goodfellowii	2	598.58	464.03
Leptotrichia shahii	3	152.79	128.74
Leptotrichia wadei	9	681.54	664.48
Leuconostoc citreum	3	183.37	46.15

Leuconostoc lactis	10	429.96	1,566.93
Leuconostoc mesenteroides	5	65.09	97.47
Lichtheimia corymbifera	9	9,539.75	146,942.20
Lichtheimia ramosa	6	2,440.46	3,281.24
Listeria monocytogenes	3	299.93	51,690.46
Lomentospora prolificans	2	1,043.36	828.85
Macrophomina phaseolina	1	5,088.66	0.00
Malassezia dermatis	1	84.77	0.00
Malassezia globosa	19	109.37	131.24
Malassezia obtusa	1	294.10	0.00
Malassezia slooffiae	1	148.67	0.00
Megasphaera micronuciformis	18	300.41	825.26
Merkel cell polyomavirus	11	126.20	386.54
Methanobrevibacter smithii	6	1,386.70	7,847.25
Meyerozyma carpophila (Candida carpophila)	1	850.50	0.00
Microbacterium maritypicum	4	21,879.00	46,834.91
Micrococcus luteus	19	80.09	114.24
Micrococcus lylae	5	251.86	432.35
Mogibacterium timidum	3	2,569.39	1,946.72
Molluscum contagiosum virus	1	128.37	0.00
Moraxella catarrhalis	67	190.58	3,101.78
Moraxella nonliquefaciens	4	110.85	95.32
Morganella morganii	9	172.14	2,192.56

Morococcus cerebrosus	59	160.88	263.25
Mucor circinelloides	7	707.09	1,792.86
Mucor indicus	4	884.52	764.34
Mucor velutinosus	4	1,267.27	3,840.99
Myceliophthora thermophila	1	2,931.91	0.00
Mycobacterium abscessus	6	123.48	93.43
Mycobacterium avium complex (MAC)	43	1,009.09	6,486.08
Mycobacterium brisbanense	1	20.42	0.00
Mycobacterium canariasense	1	8,880.45	0.00
Mycobacterium celatum	1	135.09	0.00
Mycobacterium chimaera	18	1,311.56	4,304.26
Mycobacterium fortuitum	4	11,318.29	19,170.07
Mycobacterium genavense	1	2,789.10	0.00
Mycobacterium haemophilum	3	711.97	558.62
Mycobacterium iranicum	1	3,496.88	0.00
Mycobacterium kansasii	7	283.80	1,092.27
Mycobacterium kyorinense	1	193.95	0.00
Mycobacterium mageritense	3	77.31	13.50
Mycobacterium mucogenicum	2	2,373.76	2,352.27
Mycobacterium neoaurum	1	98.35	0.00
Mycobacterium obuense	1	28.27	0.00
Mycobacterium szulgai	1	613.94	0.00
Mycobacterium tuberculosis complex	31	529.86	1,839.79

Mycobacterium xenopi	1	145.68	0.00
Mycobacteroides abscessus (Mycobacterium	10	986.83	2,176.30
abscessus)			
Mycobacteroides chelonae (Mycobacterium	3	99.55	11,021.03
chelonae)			
Mycolicibacterium brisbanense (Mycobacterium	1	31.90	0.00
brisbanense)			
Mycolicibacterium chubuense (Mycobacterium	1	60.58	0.00
chubuense)			
Mycolicibacterium elephantis (Mycobacterium	1	124.16	0.00
elephantis)			
Mycolicibacterium flavescens (Mycobacterium	1	111.66	0.00
flavescens)			
Mycolicibacterium fortuitum (Mycobacterium	1	6,851.84	0.00
fortuitum)			
Mycolicibacterium goodii (Mycobacterium	1	54.03	0.00
goodii)			
Mycolicibacterium holsaticum (Mycobacterium	1	108.30	0.00
holsaticum)			
Mycolicibacterium mageritense (Mycobacterium	3	46.13	132.81
mageritense)			
Mycolicibacterium mucogenicum	4	138.57	58.87
(Mycobacterium mucogenicum)			

Mycolicibacterium obuense (Mycobacterium	1	174.52	0.00
obuense)			
Mycolicibacterium phlei (Mycobacterium phlei)	1	100.16	0.00
Mycoplasma fermentans	1	46.76	0.00
Mycoplasma genitalium	1	72.01	0.00
Mycoplasma hominis	22	850.33	2,985.97
Mycoplasma orale	1	27,016.86	0.00
Mycoplasma pneumoniae	30	501.76	875.94
Naegleria fowleri	1	252,165.62	0.00
Nectria haematococca	8	214.71	264.23
Neisseria bacilliformis	6	84.41	125.81
Neisseria cinerea	19	189.75	436.40
Neisseria elongata	16	199.41	1,823.69
Neisseria flavescens	50	233.39	674.51
Neisseria gonorrhoeae	7	172.42	1,700.95
Neisseria lactamica	7	91.14	313.20
Neisseria meningitidis	4	742.84	923.05
Neisseria mucosa	65	263.79	747.92
Neisseria polysaccharea	1	2,405.17	0.00
Neisseria sicca	54	176.64	296.18
Neisseria weaveri	1	55.19	0.00
Nocardia abscessus	5	540.43	263.13
Nocardia africana	1	1,745.35	0.00

Nocardia alba	1	221.70	0.00
Nocardia aobensis	1	1,122.03	0.00
Nocardia arthritidis	1	316.63	0.00
Nocardia asiatica	2	634.77	331.76
Nocardia beijingensis	1	7,533.17	0.00
Nocardia brasiliensis	3	5,028.15	22,899.90
Nocardia caishijiensis	1	333.61	0.00
Nocardia coubleae	3	219.76	204.60
Nocardia cyriacigeorgica	19	2,114.43	5,435.89
Nocardia elegans	5	1,652.28	403.11
Nocardia exalbida	4	9,219.34	14,900.52
Nocardia farcinica	6	540.15	17,278.34
Nocardia gamkensis	4	8,265.16	15,257.72
Nocardia ignorata	2	223.45	40.99
Nocardia kruczakiae	1	3,074.36	0.00
Nocardia niwae	1	1,075.16	0.00
Nocardia nova	4	2,145.74	1,737.71
Nocardia pseudobrasiliensis	1	209.14	0.00
Nocardia testacea	3	6,458.07	3,689.88
Nocardia thailandica	2	160.57	9.99
Nocardia transvalensis	1	326.06	0.00
Nocardia veterana	3	248.21	1,373.42
Nocardia violaceofusca	1	1,513.97	0.00

Ochrobactrum anthropi	1	19.02	0.00
Ochrobactrum intermedium	6	67.40	44.55
Odoribacter splanchnicus	15	157.99	419.22
Oligella urethralis	1	95.29	0.00
Olsenella uli	5	304.72	222.00
Ophiostoma piceae	6	95.63	114.04
Oribacterium sinus	3	265.27	101.91
Oscillibacter ruminantium	1	2,177.92	0.00
Pantoea agglomerans	5	39.31	78.68
Pantoea ananatis	2	504.24	322.46
Parabacteroides distasonis (Bacteroides	79	269.11	630.70
distasonis)			
Parabacteroides goldsteinii	11	111.63	126.15
Parabacteroides johnsonii	1	54.45	0.00
Parabacteroides merdae (Bacteroides merdae)	23	267.04	826.60
Paraburkholderia fungorum	5	89.73	76.53
Paracoccus sanguinis	1	22.70	0.00
Paracoccus yeei	3	295.83	977.73
Parvimonas micra	38	265.51	1,536.56
Pasteurella multocida	9	261.01	4,081.62
Pediococcus acidilactici	8	484.76	1,576.94
Pediococcus pentosaceus	2	4,312.04	3,956.29
Penicillium roqueforti	4	131.69	88.00

Peptoniphilus duerdenii	1	193.15	0.00
Peptoniphilus harei	6	299.73	356.95
Peptoniphilus lacrimalis	3	3,704.81	1,953.46
Peptoniphilus rhinitidis	2	148.36	1.24
Peptostreptococcus anaerobius	8	743.25	997.75
Peptostreptococcus stomatis	10	310.75	1,377.27
Pichia kudriavzevii (Candida krusei)	11	284.86	604.41
Plasmodium ovale	1	8,863.02	0.00
Pluralibacter gergoviae	7	117.42	271.47
Pneumocystis jirovecii	258	2,452.78	18,084.89
Porphyromonas asaccharolytica	7	599.60	4,976.40
Porphyromonas gingivalis	27	527.97	2,360.78
Prevotella bivia	32	280.98	2,186.43
Prevotella buccae	12	202.19	235.67
Prevotella buccalis	2	432.39	338.45
Prevotella corporis	2	1,306.48	81.36
Prevotella denticola	49	321.99	646.21
Prevotella disiens	3	780.31	652.28
Prevotella intermedia	20	204.43	633.69
Prevotella loescheii	20	68.05	194.86
Prevotella melaninogenica	509	208.52	545.66
Prevotella nigrescens	26	124.86	309.78
Prevotella oralis	6	510.28	1,443.13

Prevotella oris	170	517.78	2,094.07
Primate bocaparvovirus 1	10	374.61	1,544.80
Primate bocaparvovirus 2	7	149.59	145.24
Primate tetraparvovirus 1 (human PARV-4)	1	264.41	0.00
Propionibacterium acidifaciens	7	81.74	112.48
Propionibacterium granulosum	4	77.79	49.63
Propionibacterium namnetense	8	236.38	505.49
Propionibacterium propionicum	5	39.72	35.85
Proteus mirabilis	50	366.80	1,256.61
Providencia alcalifaciens	2	41.88	12.50
Providencia stuartii	1	77.22	0.00
Pseudomonas aeruginosa	817	1,005.18	6,874.18
Pseudomonas alcaligenes	1	20,990.23	0.00
Pseudomonas citronellolis	9	89.74	52.47
Pseudomonas fluorescens	14	104.27	80.13
Pseudomonas luteola	5	34.43	28.69
Pseudomonas mendocina	17	65.14	56.50
Pseudomonas mosselii	3	257.67	312.30
Pseudomonas oryzihabitans	4	158.89	308.30
Pseudomonas protegens	5	98.79	116.08
Pseudomonas pseudoalcaligenes	50	85.61	106.20
Pseudomonas putida	8	105.42	160.56

Pseudopropionibacterium propionicum	5	114.00	151.83
(Propionibacterium propionicum)			
Pseudoramibacter alactolyticus	1	72.02	0.00
Psychrobacter cryohalolentis	1	161.69	0.00
Rahnella aquatilis	6	84.27	129.68
Raoultella ornithinolytica	7	259.17	11,029.63
Raoultella planticola	1	29.14	0.00
Rhizomucor miehei	7	783.55	37,761.37
Rhizomucor pusillus	39	1,324.54	19,190.65
Rhizopus delemar	23	2,464.98	8,837.62
Rhizopus microsporus	33	1,205.05	5,120.17
Rhizopus oryzae	47	745.33	5,266.62
Rhodococcus fascians	1	43.24	0.00
Rhodococcus hoagii (Rhodococcus equi)	1	98.24	0.00
Rickettsia felis	4	455.07	122,406.01
Rickettsia rickettsii	10	907.26	15,614.55
Rickettsia typhi	30	1,987.46	5,347.61
Robinsoniella peoriensis	3	4,572.89	5,006.42
Roseomonas gilardii	2	75.33	5.30
Roseomonas mucosa	3	95.21	418.92
Rothia aeria	9	454.35	441.59
Rothia dentocariosa	110	117.02	256.72
Rothia mucilaginosa	454	177.53	369.36
			1

Saccharomyces cerevisiae	86	193.62	395.44
Salmonella enterica	24	265.52	1,156.82
Scardovia wiggsiae	2	87.25	7.15
Scedosporium apiospermum	8	190.34	146.48
Scedosporium boydii	5	106.65	424.87
Scedosporium dehoogii	1	381.08	0.00
Schaalia meyeri (Actinomyces meyeri)	2	234.76	82.00
Schaalia odontolytica (Actinomyces	19	190.44	282.48
odontolyticus)			
Schistosoma mansoni	1	277.44	0.00
Serratia fonticola	2	62,730.17	62,354.35
Serratia liquefaciens	3	9,877.18	1,221,938.81
Serratia marcescens	99	492.72	2,956.54
Serratia rubidaea	1	549.62	0.00
Serratia ureilytica	3	5,444.11	5,242.95
Shigella dysenteriae	1	173.68	0.00
Shigella flexneri	4	711.85	1,964.50
Simian adenovirus 18	1	36.28	0.00
Slackia exigua	4	598.89	72,838.71
Sneathia amnii (Leptotrichia amnionii)	1	341.06	0.00
Solobacterium moorei	10	333.44	828.61
Staphylococcus argenteus	3	25,682.94	283,628.41
Staphylococcus arlettae	3	58.20	58.11

Staphylococcus auricularis 1 86.31 0.00 Staphylococcus capitis 38 149.01 541.53 Staphylococcus caprae 6 236.48 130.57 Staphylococcus cohnii 11 76.82 130.69 Staphylococcus epidermidis 716 579.58 2,689.68 Staphylococcus haemolyticus 92 1,137.08 5,450.01 Staphylococcus hominis 54 141.13 154.11 Staphylococcus lugdunensis 10 254.58 283.24 Staphylococcus pasteuri 6 159.69 270.05 Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus petudintermedius 1 145.56 0.00 Staphylococcus simulans 2 154.46 55.44 Staphylococcus simulans 2 154.46 55.44 Staphylococcus vitulinus 1 759.00 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas maltophilia 169 1,983.18 11,	Staphylococcus aureus	561	838.21	5,665.43
Staphylococcus caprae 6 236.48 130.57 Staphylococcus cohnii 11 76.82 130.69 Staphylococcus epidermidis 716 579.58 2,689.68 Staphylococcus haemolyticus 92 1,137.08 5,450.01 Staphylococcus hominis 54 141.13 154.11 Staphylococcus lugdunensis 10 254.58 283.24 Staphylococcus pasteuri 6 159.69 270.05 Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus seudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus viculinus 1 759.00 0.00 Staphylococcus virulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18	Staphylococcus auricularis	1	86.31	0.00
Staphylococcus cohnii 11 76.82 130.69 Staphylococcus epidermidis 716 579.58 2,689.68 Staphylococcus haemolyticus 92 1,137.08 5,450.01 Staphylococcus hominis 54 141.13 154.11 Staphylococcus lugdunensis 10 254.58 283.24 Staphylococcus pasteuri 6 159.69 270.05 Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus speudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 </td <td>Staphylococcus capitis</td> <td>38</td> <td>149.01</td> <td>541.53</td>	Staphylococcus capitis	38	149.01	541.53
Staphylococcus epidermidis 716 579.58 2,689.68 Staphylococcus haemolyticus 92 1,137.08 5,450.01 Staphylococcus hominis 54 141.13 154.11 Staphylococcus lugdunensis 10 254.58 283.24 Staphylococcus pasteuri 6 159.69 270.05 Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus seudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus viccinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683	Staphylococcus caprae	6	236.48	130.57
Staphylococcus haemolyticus 92 1,137.08 5,450.01 Staphylococcus hominis 54 141.13 154.11 Staphylococcus lugdunensis 10 254.58 283.24 Staphylococcus pasteuri 6 159.69 270.05 Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus pseudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus cohnii	11	76.82	130.69
Staphylococcus hominis 54 141.13 154.11 Staphylococcus lugdunensis 10 254.58 283.24 Staphylococcus pasteuri 6 159.69 270.05 Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus speudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus epidermidis	716	579.58	2,689.68
Staphylococcus lugdunensis 10 254.58 283.24 Staphylococcus pasteuri 6 159.69 270.05 Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus pseudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus haemolyticus	92	1,137.08	5,450.01
Staphylococcus pasteuri 6 159.69 270.05 Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus pseudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus hominis	54	141.13	154.11
Staphylococcus pettenkoferi 6 122.64 126.34 Staphylococcus pseudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus lugdunensis	10	254.58	283.24
Staphylococcus pseudintermedius 1 145.56 0.00 Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus pasteuri	6	159.69	270.05
Staphylococcus saprophyticus 6 194.65 143.45 Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus pettenkoferi	6	122.64	126.34
Staphylococcus simulans 2 154.46 55.44 Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus pseudintermedius	1	145.56	0.00
Staphylococcus succinus 1 759.00 0.00 Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus saprophyticus	6	194.65	143.45
Staphylococcus vitulinus 1 615.92 0.00 Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus simulans	2	154.46	55.44
Staphylococcus warneri 9 193.36 103.19 Stenotrophomonas acidaminiphila 2 40.38 4.36 Stenotrophomonas maltophilia 169 1,983.18 11,864.14 Streptobacillus moniliformis 6 202.09 238.18 Streptococcus agalactiae 71 1,683.20 8,449.36	Staphylococcus succinus	1	759.00	0.00
Stenotrophomonas acidaminiphila240.384.36Stenotrophomonas maltophilia1691,983.1811,864.14Streptobacillus moniliformis6202.09238.18Streptococcus agalactiae711,683.208,449.36	Staphylococcus vitulinus	1	615.92	0.00
Stenotrophomonas maltophilia1691,983.1811,864.14Streptobacillus moniliformis6202.09238.18Streptococcus agalactiae711,683.208,449.36	Staphylococcus warneri	9	193.36	103.19
Streptobacillus moniliformis6202.09238.18Streptococcus agalactiae711,683.208,449.36	Stenotrophomonas acidaminiphila	2	40.38	4.36
Streptococcus agalactiae 71 1,683.20 8,449.36	Stenotrophomonas maltophilia	169	1,983.18	11,864.14
	Streptobacillus moniliformis	6	202.09	238.18
Streptococcus anginosus 52 312.50 628.82	Streptococcus agalactiae	71	1,683.20	8,449.36
	Streptococcus anginosus	52	312.50	628.82
Streptococcus canis 2 465.07 256.92	Streptococcus canis	2	465.07	256.92

Streptococcus constellatus	29	468.43	852.02
Streptococcus cristatus	3	444.40	211.52
Streptococcus dentisani	2	155.06	78.75
Streptococcus dysgalactiae	22	406.07	1,255.37
Streptococcus equi	2	6,266.23	5,506.19
Streptococcus gallolyticus	3	22,946.94	41,268.98
Streptococcus gordonii	20	180.63	491.75
Streptococcus infantarius	16	171.27	355.90
Streptococcus infantis	28	99.88	223.43
Streptococcus intermedius	100	354.95	1,048.47
Streptococcus lutetiensis	3	213.22	370.59
Streptococcus macedonicus	3	339.48	277.02
Streptococcus massiliensis	2	2,225.28	1,102.37
Streptococcus mitis	356	226.15	897.48
Streptococcus mutans	8	948.77	4,349.85
Streptococcus oralis	140	235.54	730.42
Streptococcus oralis subsp. Dentisani	2	54,008.79	53,104.88
(Streptococcus dentisani)			
Streptococcus oralis subsp. tigurinus	14	141.23	673.16
(Streptococcus tigurinus)			
Streptococcus parasanguinis	186	152.35	298.03
Streptococcus pasteurianus	9	2,240.75	2,414.70
Streptococcus peroris	20	106.46	245.34

Streptococcus pneumoniae	214	975.48	11,933.10
Streptococcus pseudopneumoniae	15	766.78	9,286.51
Streptococcus pyogenes	95	1,064.08	9,773.54
Streptococcus salivarius	104	253.73	799.10
Streptococcus sanguinis	27	269.26	1,348.95
Streptococcus sobrinus	3	96.96	173.72
Streptococcus suis	2	145.34	89.41
Streptococcus thermophilus	184	190.84	339.33
Streptococcus tigurinus	17	144.78	1,095.78
Streptococcus vestibularis	10	202.38	422.82
Streptomyces cattleya	16	114.74	55.64
Strongyloides stercoralis	4	1,512.96	9,478.02
Sutterella wadsworthensis	31	565.51	1,227.99
Syncephalastrum monosporum	2	568.75	6.29
Tannerella forsythia	5	473.15	207.68
Tannerella forsythia (Bacteroides forsythus)	6	174.58	2,910.62
Tatlockia micdadei (Legionella micdadei)	5	3,688.83	2,863.47
Terrisporobacter othiniensis	1	100.14	0.00
Thermothelomyces thermophilus	1	7,097.68	0.00
(Myceliophthora thermophila)			
Thielavia terrestris	1	4,992.52	0.00
Torque teno virus	135	484.19	1,935.97
Torque teno virus 1	7	236.02	200.42

Torque teno virus 10	19	427.60	963.21
Torque teno virus 12	9	289.68	1,425.06
Torque teno virus 15	48	354.03	808.26
Torque teno virus 16	69	314.22	883.45
Torque teno virus 19	8	150.95	221.08
Torque teno virus 27	5	580.18	395.77
Torque teno virus 28	13	501.20	1,455.28
Torque teno virus 3	6	1,069.93	1,952.05
Torque teno virus 6	25	235.89	1,976.02
Torque teno virus 7	4	313.65	39,910.86
Torque teno virus 8	3	141.72	75.53
Toxoplasma gondii	39	5,412.46	104,051.17
Treponema pallidum	9	8,026.35	18,627.59
Trichoderma atroviride	2	360.84	334.43
Trichoderma gamsii	1	20.36	0.00
Trichoderma harzianum	1	1,179.46	0.00
Trichoderma longibrachiatum	6	618.09	545.78
Trichodysplasia spinulosa-associated	34	321.17	2,290.78
polyomavirus			
Trichomonas vaginalis	5	676.48	10,184.71
Trichosporon asahii	14	488.22	1,544.34
Trichosporon faecale	1	38.11	0.00
Tropheryma whipplei	2	412.51	353.73

Trypanosoma cruzi	2	20,291.83	19,786.23
Tsukamurella pulmonis	1	34,399.13	0.00
Ureaplasma parvum	28	490.84	1,927.18
Ureaplasma urealyticum	14	256.95	6,202.13
Varicella-zoster virus (VZV)	48	1,856.17	7,412.46
Veillonella dispar	162	140.88	269.85
Veillonella parvula	256	202.30	476.57
Verruconis gallopava (Ochroconis gallopava)	1	228.74	0.00
Vittaforma corneae	1	147.95	0.00
Wallemia mellicola	2	79.97	13.00
Weeksella virosa	1	7,762.15	0.00
Weissella confusa	9	127.19	416.59
Wickerhamomyces anomalus (Pichia anomala)	2	1,656.22	12.29
Winkia neuii (Actinomyces neuii)	2	279.78	169.83
WU Polyomavirus	19	333.12	1,721.87

Supplemental Table 2. Reports with co-detections of *Legionella* spp., *Nocardia* spp., and *Mycobacterium* spp., April 2018–September 2021.

Sample number	Genus	Taxa name	MPM
1	Legionella spp.	L. brunensis	401
		L. hackeliae	270
		Epstein-Barr virus (EBV)	1,405
2	Legionella spp.	L. feeleii	78,508
		L. tunisiensis	76,445
		Aspergillus fumigatus	594
		Encephalitozoon hellem	739
3	Nocardia spp.	N. alba	222
		N. caishijiensis	334
		N. coubleae	495
		N. ignorata	182
		N. thailandica	171
		Human adenovirus D	747
		Prevotella melaninogenica	283
4	Nocardia spp.	N. exalbida	17,384
		N. gamkensis	22,906
5	Nocardia spp.	N. exalbida	2,153
		N. gamkensis	1,871
6	Nocardia spp.	N. exalbida	182
		N. gamkensis	242

		BK polyomavirus	81
		Pseudomonas aeruginosa	498
7	Nocardia spp.	N. elegans	131
		N. nova	440
		Actinomyces oris	150
		Bacteroides vulgatus	215
		Corynebacterium striatum	1,590
		Enterococcus faecalis	296
		Lactobacillus fermentum	117
		Lomentospora prolificans	215
		Prevotella buccae	138
		Prevotella oralis	209
		Rothia mucilaginosa	874
		Staphylococcus aureus	364
		Streptococcus salivarius	1,032
		Veillonella parvula	122
8	Nocardia spp.	N. africana	1,745
		N. elegans	6,314
		N. nova	3,945
		Cytomegalovirus (CMV)	12,597
9	Nocardia spp.	N. abscessus	619
		N. arthritidis	317
		N. asiatica	303

10	Nocardia spp.	N. elegans	1,556
		N. nova	2,720
11	Nocardia spp.	N. elegans	1,652
		N. nova	1,572
12	Nocardia spp.	N. exalbida	16,286
		N. gamkensis	14,660
		JC polyomavirus	337
13	Nocardia spp.	N. coubleae	220
		N. ignorata	264
		N. thailandica	151
		Cytomegalovirus (CMV)	81
		Human adenovirus D	692
14	Nocardia spp.	N. aobensis	1,122
		N. kruczakiae	3,074
		N. violaceofusca	1,514
		Aspergillus fumigatus	4,204
		BK polyomavirus	2,260
		Epstein-Barr virus (EBV)	49
		JC polyomavirus	61
15	Mycobacterium spp.	M. brisbanense	20
		M. mucogenicum	21
		M. obuense	28
		Stenotrophomonas acidaminiphila	36
		1	l.

16	Mycobacterium spp.	M. chubuense	61
		M. elephantis	124
		M. flavescens	112
		M. goodii	54
		M. holsaticum	108
		M. phlei	100
		Neisseria meningitidis	62
17	Mycobacterium spp.	M. avium complex (MAC)	441
		M. celatum	135
		M. kyorinense	194
		Epstein-Barr virus (EBV)	155
		Prevotella melaninogenica	398
		Rothia mucilaginosa	913
		Veillonella dispar	236
		Veillonella parvula	122
18	Mycobacterium spp.	M. avium complex (MAC)	8,039
		M. chimaera	2,410
19	Mycobacterium spp.	M. avium complex (MAC)	104
		M. chimaera	104
20	Mycobacterium spp.	M. complex (MAC)	36,867
		M. chimaera	36,862

Fig. 1. Number of detections by the Karius test of the different super groups of taxa, Apr 2018–Sept 2021, N=22,792: bacteria, 16,221; viruses, 4,737; fungi, 1,758; parasites, 70. Percentages reflect proportion of total number of detections.




Fig. 2. Number of detected taxa counts per report for all positive reports, Apr 2018–Sept 2021. Percentages reflect the proportion of all positive reports (N=10,752).




Fig. 3. Frequency distribution of different *Legionella*-like organisms detected, n=80 (< 1% of all bacterial detections, N=16,203). *Indicates species not previously detected in humans.




Fig. 4. Frequency distribution of Nocardia spp. detections, n=76 (< 1% bacterial detections, N=16,203). *Indicates species more frequently isolated from clinical specimens (69). †Indicates species-specific susceptibility patterns (54).




Fig. 5. Frequency distribution of *Mycobacterium* spp. detections, n=156 (1% of all bacterial detections, N=16,203). *Indicates slowly growing mycobacteria of established clinical significance (70). †Indicates rapidly growing mycobacteria considered common human pathogens. ‡Indicates rapidly growing mycobacteria considered less common or rare human pathogens (71).




Fig. 6. Frequency distribution of zoonotic and vector borne bacteria detections, n=247 (2%of all bacterial detections, N=16,203). *Indicates bacteria causing a nationally notifiable infectious disease (72).




Fig. 7. Frequency distribution of *Candida* spp. detections, n=648 (36% of all fungal detections, N=1,776).




Fig. 8. Frequency distribution of Aspergillus spp. detections, n=374 (21% of all fungal detections, N=1,776). *Indicates most common pathogenic species.




Fig 9. Frequency distribution of detections in the order Mucorales, n=196 (11% of all fungal detections, N=1,776). *Indicates taxa implicated in human mucormycosis (73).




Fig 10. Frequency distribution of detections of systemic dimorphic fungi, n=78 (4% of all fungal detections, N=1,776).




Fig 11. Frequency distribution of detections of dematiaceous fungi, n=33 (2% of all fungal detections, N=1,776).




Fig 12. Frequency distribution of detections of protozoan parasites, n=57 (89% of all eukaryotic parasite detections, N=64).

